https://spypharm.com/rss/category/pharmaceutical SpyPharm | Pharmaceutical News, Developments & Trends & : Pharmaceutical en Copyright 2023 Spypharm & All Rights Reserved. https://spypharm.com/ionis-and-sobi-agree-on-olezarsen-commercialisation https://spypharm.com/ionis-and-sobi-agree-on-olezarsen-commercialisation Sat, 29 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/blockbuster-potential-drugs-ruled-the-2024-pipeline-with-53-rise-over-2023 https://spypharm.com/blockbuster-potential-drugs-ruled-the-2024-pipeline-with-53-rise-over-2023 Sat, 29 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/how-bioconjugation-is-unlocking-the-next-generation-of-drug-development https://spypharm.com/how-bioconjugation-is-unlocking-the-next-generation-of-drug-development Sat, 29 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/macau-approves-iaso-bios-multiple-myeloma-therapy https://spypharm.com/macau-approves-iaso-bios-multiple-myeloma-therapy Sat, 29 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/weill-cancer-hub-east-launches-to-transform-treatment https://spypharm.com/weill-cancer-hub-east-launches-to-transform-treatment Sat, 29 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/genmabs-tivdak-approved-in-japan-for-advanced-cervical-cancer https://spypharm.com/genmabs-tivdak-approved-in-japan-for-advanced-cervical-cancer Sat, 29 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/soleno-wins-fda-approval-for-prader-willi-hyperphagia-treatment https://spypharm.com/soleno-wins-fda-approval-for-prader-willi-hyperphagia-treatment Sat, 29 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/hhs-announces-major-workforce-cuts-and-reorganisation https://spypharm.com/hhs-announces-major-workforce-cuts-and-reorganisation Sat, 29 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/novo-nordisk-strikes-1bn-deal-for-lexicons-oral-obesity-drug https://spypharm.com/novo-nordisk-strikes-1bn-deal-for-lexicons-oral-obesity-drug Sat, 29 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/msds-subcutaneous-keytruda-non-inferior-to-iv-version-of-blockbuster-drug https://spypharm.com/msds-subcutaneous-keytruda-non-inferior-to-iv-version-of-blockbuster-drug Sat, 29 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/fda-fast-tracks-sanofis-mrna-vaccine-for-chlamydia https://spypharm.com/fda-fast-tracks-sanofis-mrna-vaccine-for-chlamydia Thu, 27 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/msd-makes-licence-agreement-with-hengrui-pharma-for-lpa-inhibitor https://spypharm.com/msd-makes-licence-agreement-with-hengrui-pharma-for-lpa-inhibitor Thu, 27 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/mhra-launches-new-monthly-safety-bulletins https://spypharm.com/mhra-launches-new-monthly-safety-bulletins Thu, 27 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/cassava-ends-simufilam-alzheimers-programme-after-second-phase-iii-failure https://spypharm.com/cassava-ends-simufilam-alzheimers-programme-after-second-phase-iii-failure Thu, 27 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/character-biosciences-gains-93m-for-precision-eye-disease-therapies https://spypharm.com/character-biosciences-gains-93m-for-precision-eye-disease-therapies Thu, 27 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/eu-health-data-space-strikes-a-chord-in-eu-harmonisation-plans https://spypharm.com/eu-health-data-space-strikes-a-chord-in-eu-harmonisation-plans Thu, 27 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/unmatched-quality-in-pharmaceutical-logistics-why-it-matters https://spypharm.com/unmatched-quality-in-pharmaceutical-logistics-why-it-matters Thu, 27 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/fda-approves-gsks-blujepa-for-uncomplicated-utis https://spypharm.com/fda-approves-gsks-blujepa-for-uncomplicated-utis Thu, 27 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/big-pharma-faces-headwinds-in-china-as-vaccine-sales-decline https://spypharm.com/big-pharma-faces-headwinds-in-china-as-vaccine-sales-decline Thu, 27 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/ec-approves-msds-pneumococcal-21-valent-conjugate-capvaxive https://spypharm.com/ec-approves-msds-pneumococcal-21-valent-conjugate-capvaxive Thu, 27 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/alberta-partners-siemens-and-the-alberta-cancer-foundation https://spypharm.com/alberta-partners-siemens-and-the-alberta-cancer-foundation Tue, 25 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/rising-sirturo-resistance-highlights-urgent-need-for-new-tb-therapies https://spypharm.com/rising-sirturo-resistance-highlights-urgent-need-for-new-tb-therapies Tue, 25 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/fda-approves-ind-application-for-everests-cancer-vaccine https://spypharm.com/fda-approves-ind-application-for-everests-cancer-vaccine Tue, 25 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/astrazeneca-to-invest-25bn-in-rd-centre-in-china https://spypharm.com/astrazeneca-to-invest-25bn-in-rd-centre-in-china Tue, 25 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/jj-boosts-us-operations-with-55bn-investment https://spypharm.com/jj-boosts-us-operations-with-55bn-investment Tue, 25 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/valneva-outlays-40000-vaccines-to-reunion-amidst-chikungunya-surge https://spypharm.com/valneva-outlays-40000-vaccines-to-reunion-amidst-chikungunya-surge Tue, 25 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/augustine-secures-85m-to-advance-charcot-marie-tooth-candidate https://spypharm.com/augustine-secures-85m-to-advance-charcot-marie-tooth-candidate Tue, 25 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/alnylam-challenges-pfizer-and-bridgebio-with-fda-nod-for-attr-cm-drug https://spypharm.com/alnylam-challenges-pfizer-and-bridgebio-with-fda-nod-for-attr-cm-drug Tue, 25 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/sermonix-and-regor-to-enhance-breast-cancer-treatment-options https://spypharm.com/sermonix-and-regor-to-enhance-breast-cancer-treatment-options Tue, 25 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/tempero-secures-70m-to-advance-addiction-treatment-candidate https://spypharm.com/tempero-secures-70m-to-advance-addiction-treatment-candidate Tue, 25 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/european-agencies-catch-up-with-speedier-regulatory-pathways-for-cgts-in-the-us https://spypharm.com/european-agencies-catch-up-with-speedier-regulatory-pathways-for-cgts-in-the-us Sun, 23 Mar 2025 06:00:11 -0400 spectro https://spypharm.com/menarini-to-enhance-bpdcn-detection-with-visualdxs-link https://spypharm.com/menarini-to-enhance-bpdcn-detection-with-visualdxs-link Sun, 23 Mar 2025 06:00:11 -0400 spectro https://spypharm.com/china-conditionally-approves-hutchmeds-tazverik-for-follicular-lymphoma https://spypharm.com/china-conditionally-approves-hutchmeds-tazverik-for-follicular-lymphoma Sun, 23 Mar 2025 06:00:11 -0400 spectro https://spypharm.com/global-funding-cuts-reversing-decades-of-tuberculosis-progress-who-says https://spypharm.com/global-funding-cuts-reversing-decades-of-tuberculosis-progress-who-says Sun, 23 Mar 2025 06:00:11 -0400 spectro https://spypharm.com/how-to-manage-regulatory-complexities-with-clinical-trial-data https://spypharm.com/how-to-manage-regulatory-complexities-with-clinical-trial-data Sun, 23 Mar 2025 06:00:11 -0400 spectro https://spypharm.com/funding-drought-how-can-biotech-and-biopharma-keep-trials-running https://spypharm.com/funding-drought-how-can-biotech-and-biopharma-keep-trials-running Sun, 23 Mar 2025 06:00:11 -0400 spectro https://spypharm.com/pfizer-sells-73-stake-in-haleon-for-33bn https://spypharm.com/pfizer-sells-73-stake-in-haleon-for-33bn Fri, 21 Mar 2025 06:00:20 -0400 spectro https://spypharm.com/oxford-biotherapeutics-and-roche-link-on-antibody-cancer-treatments https://spypharm.com/oxford-biotherapeutics-and-roche-link-on-antibody-cancer-treatments Fri, 21 Mar 2025 06:00:20 -0400 spectro https://spypharm.com/blood-cancers-dominate-car-t-pipeline https://spypharm.com/blood-cancers-dominate-car-t-pipeline Fri, 21 Mar 2025 06:00:20 -0400 spectro https://spypharm.com/allogeneic-cell-therapies-poised-for-prime-time-says-expert https://spypharm.com/allogeneic-cell-therapies-poised-for-prime-time-says-expert Fri, 21 Mar 2025 06:00:20 -0400 spectro https://spypharm.com/uspto-allows-patents-for-remedys-large-hemispheric-infarction-drug https://spypharm.com/uspto-allows-patents-for-remedys-large-hemispheric-infarction-drug Fri, 21 Mar 2025 06:00:20 -0400 spectro https://spypharm.com/fda-approves-johnson-johnsons-tremfya-to-treat-crohns-disease https://spypharm.com/fda-approves-johnson-johnsons-tremfya-to-treat-crohns-disease Fri, 21 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/sanofi-outlays-19bn-to-purchase-dren-bios-bispecific-antibody https://spypharm.com/sanofi-outlays-19bn-to-purchase-dren-bios-bispecific-antibody Fri, 21 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/servier-and-black-diamond-sign-deal-for-solid-tumours-therapy https://spypharm.com/servier-and-black-diamond-sign-deal-for-solid-tumours-therapy Fri, 21 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/international-reference-pricing-irp-2024-a-year-in-review https://spypharm.com/international-reference-pricing-irp-2024-a-year-in-review Fri, 21 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/roches-discontinued-alzheimers-drug-shows-signs-of-preventing-onset https://spypharm.com/roches-discontinued-alzheimers-drug-shows-signs-of-preventing-onset Fri, 21 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/health-canada-approves-biogens-skyclarys-for-friedreichs-ataxia https://spypharm.com/health-canada-approves-biogens-skyclarys-for-friedreichs-ataxia Wed, 19 Mar 2025 06:00:19 -0400 spectro https://spypharm.com/astrazeneca-and-alteogen-agree-on-alt-b4-platform-tech https://spypharm.com/astrazeneca-and-alteogen-agree-on-alt-b4-platform-tech Wed, 19 Mar 2025 06:00:19 -0400 spectro https://spypharm.com/latigo-secures-150m-for-non-opioid-pain-treatment-development https://spypharm.com/latigo-secures-150m-for-non-opioid-pain-treatment-development Wed, 19 Mar 2025 06:00:19 -0400 spectro https://spypharm.com/big-tech-meets-biotech-recursion-and-the-ai-gold-rush-in-pharma https://spypharm.com/big-tech-meets-biotech-recursion-and-the-ai-gold-rush-in-pharma Wed, 19 Mar 2025 06:00:19 -0400 spectro https://spypharm.com/investigating-key-strategies-for-optimising-clinical-trial-supply-chains-in-2025 https://spypharm.com/investigating-key-strategies-for-optimising-clinical-trial-supply-chains-in-2025 Wed, 19 Mar 2025 06:00:19 -0400 spectro https://spypharm.com/incyte-stock-hit-11-despite-paediatric-dermatology-trials-hitting-target https://spypharm.com/incyte-stock-hit-11-despite-paediatric-dermatology-trials-hitting-target Wed, 19 Mar 2025 06:00:19 -0400 spectro https://spypharm.com/clinical-trial-challenges-in-china-how-a-sharp-and-clinschain-pairing-is-breaking-down-barriers https://spypharm.com/clinical-trial-challenges-in-china-how-a-sharp-and-clinschain-pairing-is-breaking-down-barriers Wed, 19 Mar 2025 06:00:19 -0400 spectro https://spypharm.com/curevo-procures-110m-and-former-gsk-exec-for-shingles-vaccine-candidate https://spypharm.com/curevo-procures-110m-and-former-gsk-exec-for-shingles-vaccine-candidate Wed, 19 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/arbor-to-advance-gene-editing-treatments-with-739m-funding https://spypharm.com/arbor-to-advance-gene-editing-treatments-with-739m-funding Wed, 19 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/opko-and-entera-focus-on-oral-care-for-obesity-and-metabolic-disorders https://spypharm.com/opko-and-entera-focus-on-oral-care-for-obesity-and-metabolic-disorders Wed, 19 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/ec-approves-bristol-myers-squibbs-follicular-lymphoma-car-t-therapy https://spypharm.com/ec-approves-bristol-myers-squibbs-follicular-lymphoma-car-t-therapy Mon, 17 Mar 2025 06:00:18 -0400 spectro https://spypharm.com/boehringer-ingelheim-and-salipro-enter-drug-discovery-partnership https://spypharm.com/boehringer-ingelheim-and-salipro-enter-drug-discovery-partnership Sat, 15 Mar 2025 06:00:22 -0400 spectro https://spypharm.com/ec-approves-otsuka-and-lundbecks-rxultifor-schizophrenia https://spypharm.com/ec-approves-otsuka-and-lundbecks-rxultifor-schizophrenia Sat, 15 Mar 2025 06:00:22 -0400 spectro https://spypharm.com/insilico-raises-110m-to-develop-drug-pipeline-and-ai-platform https://spypharm.com/insilico-raises-110m-to-develop-drug-pipeline-and-ai-platform Sat, 15 Mar 2025 06:00:22 -0400 spectro https://spypharm.com/gedeon-richters-once-daily-endometriosis-pill-approved-for-nhs-use https://spypharm.com/gedeon-richters-once-daily-endometriosis-pill-approved-for-nhs-use Sat, 15 Mar 2025 06:00:22 -0400 spectro https://spypharm.com/mallinckrodt-and-endo-sign-67bn-merger-deal https://spypharm.com/mallinckrodt-and-endo-sign-67bn-merger-deal Sat, 15 Mar 2025 06:00:22 -0400 spectro https://spypharm.com/emergent-signs-financial-investment-agreement-with-swiss-rockets https://spypharm.com/emergent-signs-financial-investment-agreement-with-swiss-rockets Sat, 15 Mar 2025 06:00:22 -0400 spectro https://spypharm.com/astrazeneca-director-says-ai-must-be-a-thought-partner-in-drug-discovery https://spypharm.com/astrazeneca-director-says-ai-must-be-a-thought-partner-in-drug-discovery Sat, 15 Mar 2025 06:00:22 -0400 spectro https://spypharm.com/meiragtx-and-hologen-launch-ai-backed-gene-therapy-venture https://spypharm.com/meiragtx-and-hologen-launch-ai-backed-gene-therapy-venture Sat, 15 Mar 2025 06:00:22 -0400 spectro https://spypharm.com/vivani-treats-first-patient-with-long-lasting-drug-implant-for-weight-loss https://spypharm.com/vivani-treats-first-patient-with-long-lasting-drug-implant-for-weight-loss Sat, 15 Mar 2025 06:00:22 -0400 spectro https://spypharm.com/unsafe-and-unregulated-cell-therapies-being-sold-in-europe https://spypharm.com/unsafe-and-unregulated-cell-therapies-being-sold-in-europe Sat, 15 Mar 2025 06:00:21 -0400 spectro https://spypharm.com/vori-health-secures-53m-funding-to-support-musculoskeletal-care https://spypharm.com/vori-health-secures-53m-funding-to-support-musculoskeletal-care Thu, 13 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/zealand-and-roche-strike-53bn-obesity-treatment-deal https://spypharm.com/zealand-and-roche-strike-53bn-obesity-treatment-deal Thu, 13 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/canada-and-alberta-governments-to-invest-in-entos-rd-facility https://spypharm.com/canada-and-alberta-governments-to-invest-in-entos-rd-facility Thu, 13 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/wuxi-xdc-and-abtis-collaborate-on-antibody-drug-conjugates https://spypharm.com/wuxi-xdc-and-abtis-collaborate-on-antibody-drug-conjugates Thu, 13 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/viking-strikes-150m-deal-to-secure-supply-of-obesity-drug https://spypharm.com/viking-strikes-150m-deal-to-secure-supply-of-obesity-drug Thu, 13 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/bms-to-acquire-longtime-cell-therapy-partner-2seventy-bio-for-286m https://spypharm.com/bms-to-acquire-longtime-cell-therapy-partner-2seventy-bio-for-286m Thu, 13 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/atsenas-atsn-201-gains-fda-fast-track-status-for-xlrs-treatment https://spypharm.com/atsenas-atsn-201-gains-fda-fast-track-status-for-xlrs-treatment Thu, 13 Mar 2025 06:00:15 -0400 spectro https://spypharm.com/orphelia-explores-avenues-for-liquid-neuroblastoma-med-after-eu-chmp-rejection https://spypharm.com/orphelia-explores-avenues-for-liquid-neuroblastoma-med-after-eu-chmp-rejection Thu, 13 Mar 2025 06:00:15 -0400 spectro https://spypharm.com/ono-earmarks-940m-to-gain-rare-blood-cancer-therapy-from-ionis https://spypharm.com/ono-earmarks-940m-to-gain-rare-blood-cancer-therapy-from-ionis Thu, 13 Mar 2025 06:00:15 -0400 spectro https://spypharm.com/envirotainer-expands-cold-chain-solutions-portfolio-to-cover-all-pharma-segments-sizes-and-temperatures https://spypharm.com/envirotainer-expands-cold-chain-solutions-portfolio-to-cover-all-pharma-segments-sizes-and-temperatures Thu, 13 Mar 2025 06:00:15 -0400 spectro https://spypharm.com/roche-announces-hub-for-cardiovascular-renal-and-metabolism-research https://spypharm.com/roche-announces-hub-for-cardiovascular-renal-and-metabolism-research Tue, 11 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/alliance-pharma-agrees-to-362m-acquisition-by-dbay https://spypharm.com/alliance-pharma-agrees-to-362m-acquisition-by-dbay Tue, 11 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/ec-approves-bms-opdivo-and-yervoy-combo-for-hcc https://spypharm.com/ec-approves-bms-opdivo-and-yervoy-combo-for-hcc Tue, 11 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/sun-pharma-agrees-to-acquire-checkpoint-therapeutics https://spypharm.com/sun-pharma-agrees-to-acquire-checkpoint-therapeutics Tue, 11 Mar 2025 06:00:17 -0400 spectro https://spypharm.com/kenox-and-lactiga-partner-on-siga-therapies-for-immunodeficiency https://spypharm.com/kenox-and-lactiga-partner-on-siga-therapies-for-immunodeficiency Tue, 11 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/astrazeneca-and-ionis-win-eu-approval-for-attr-polyneuropathy https://spypharm.com/astrazeneca-and-ionis-win-eu-approval-for-attr-polyneuropathy Tue, 11 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/vaccinex-plans-nasdaq-exit-as-alzheimer-market-pressure-grows https://spypharm.com/vaccinex-plans-nasdaq-exit-as-alzheimer-market-pressure-grows Tue, 11 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/artificial-intelligence-is-making-clinical-supply-chains-more-efficient-and-more-sustainable-heres-how https://spypharm.com/artificial-intelligence-is-making-clinical-supply-chains-more-efficient-and-more-sustainable-heres-how Tue, 11 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/ia-2a-positivity-identified-as-a-key-predictor-in-type-1-diabetes-progression https://spypharm.com/ia-2a-positivity-identified-as-a-key-predictor-in-type-1-diabetes-progression Tue, 11 Mar 2025 06:00:16 -0400 spectro https://spypharm.com/fda-odd-given-to-plus-therapeutics-injectable-radiotherapy https://spypharm.com/fda-odd-given-to-plus-therapeutics-injectable-radiotherapy Sun, 09 Mar 2025 06:00:10 -0400 spectro https://spypharm.com/uks-pricing-watchdog-rejects-alzheimer-treatments-for-the-second-time https://spypharm.com/uks-pricing-watchdog-rejects-alzheimer-treatments-for-the-second-time Sun, 09 Mar 2025 06:00:09 -0400 spectro https://spypharm.com/jj-drops-phase-iii-mdd-programme-due-to-lack-of-efficacy https://spypharm.com/jj-drops-phase-iii-mdd-programme-due-to-lack-of-efficacy Sun, 09 Mar 2025 06:00:09 -0400 spectro https://spypharm.com/fda-approves-scpharmaceuticals-furoscix-snda-for-oedema-in-ckd https://spypharm.com/fda-approves-scpharmaceuticals-furoscix-snda-for-oedema-in-ckd Sun, 09 Mar 2025 06:00:09 -0400 spectro https://spypharm.com/the-trillion-dollar-opportunity-in-womens-health https://spypharm.com/the-trillion-dollar-opportunity-in-womens-health Sun, 09 Mar 2025 06:00:09 -0400 spectro https://spypharm.com/astellas-and-yaskawa-form-jv-for-cell-therapy-product-manufacture https://spypharm.com/astellas-and-yaskawa-form-jv-for-cell-therapy-product-manufacture Fri, 07 Mar 2025 06:00:17 -0500 spectro https://spypharm.com/itm-targets-us-approval-for-radiopharmaceutical-after-phase-iii-readout https://spypharm.com/itm-targets-us-approval-for-radiopharmaceutical-after-phase-iii-readout Fri, 07 Mar 2025 06:00:17 -0500 spectro https://spypharm.com/tris-pharma-eyes-approval-after-pain-drug-triumphs-in-second-phase-iii-trial https://spypharm.com/tris-pharma-eyes-approval-after-pain-drug-triumphs-in-second-phase-iii-trial Fri, 07 Mar 2025 06:00:17 -0500 spectro https://spypharm.com/tc-biopharm-signs-loi-to-acquire-ophthalmic-pharma-company https://spypharm.com/tc-biopharm-signs-loi-to-acquire-ophthalmic-pharma-company Fri, 07 Mar 2025 06:00:17 -0500 spectro https://spypharm.com/novo-nordisk-cuts-wegovy-price-through-new-direct-to-patient-online-pharmacy https://spypharm.com/novo-nordisk-cuts-wegovy-price-through-new-direct-to-patient-online-pharmacy Fri, 07 Mar 2025 06:00:17 -0500 spectro https://spypharm.com/trimtech-closes-seed-fund-round-to-advance-cns-therapeutics-pipeline https://spypharm.com/trimtech-closes-seed-fund-round-to-advance-cns-therapeutics-pipeline Fri, 07 Mar 2025 06:00:17 -0500 spectro https://spypharm.com/understanding-the-rules-on-hpapi-containment-in-high-potent-manufacturing https://spypharm.com/understanding-the-rules-on-hpapi-containment-in-high-potent-manufacturing Fri, 07 Mar 2025 06:00:17 -0500 spectro https://spypharm.com/tumour-on-chip-model-could-help-discover-pancreatic-cancer-therapies https://spypharm.com/tumour-on-chip-model-could-help-discover-pancreatic-cancer-therapies Fri, 07 Mar 2025 06:00:17 -0500 spectro https://spypharm.com/merck-kgaa-reports-ye24-earnings-growth-amid-springworks-acquisition-talks https://spypharm.com/merck-kgaa-reports-ye24-earnings-growth-amid-springworks-acquisition-talks Fri, 07 Mar 2025 06:00:17 -0500 spectro https://spypharm.com/project-optimus-the-evolution-of-dose-optimisation-in-oncology https://spypharm.com/project-optimus-the-evolution-of-dose-optimisation-in-oncology Fri, 07 Mar 2025 06:00:17 -0500 spectro https://spypharm.com/callio-raises-187m-for-proof-of-concept-for-dual-payload-adc https://spypharm.com/callio-raises-187m-for-proof-of-concept-for-dual-payload-adc Wed, 05 Mar 2025 06:00:18 -0500 spectro https://spypharm.com/are-european-biopharma-manufacturers-nearshoring https://spypharm.com/are-european-biopharma-manufacturers-nearshoring Wed, 05 Mar 2025 06:00:18 -0500 spectro https://spypharm.com/machine-learning-adoption-into-supply-chain-management-on-the-horizon https://spypharm.com/machine-learning-adoption-into-supply-chain-management-on-the-horizon Wed, 05 Mar 2025 06:00:18 -0500 spectro https://spypharm.com/reflecting-on-a-milestone-year-for-cell-and-gene-therapies https://spypharm.com/reflecting-on-a-milestone-year-for-cell-and-gene-therapies Wed, 05 Mar 2025 06:00:18 -0500 spectro https://spypharm.com/genentech-wins-fda-approval-for-second-stroke-treatment https://spypharm.com/genentech-wins-fda-approval-for-second-stroke-treatment Wed, 05 Mar 2025 06:00:18 -0500 spectro https://spypharm.com/eu-set-to-approve-astrazenecas-imfinzi-chemo-combo-for-nsclc https://spypharm.com/eu-set-to-approve-astrazenecas-imfinzi-chemo-combo-for-nsclc Wed, 05 Mar 2025 06:00:18 -0500 spectro https://spypharm.com/mwc-barcelona-2025-huawei-unveils-global-showcases-alongside-customers-and-launches-10-industry-solutions-with-partners https://spypharm.com/mwc-barcelona-2025-huawei-unveils-global-showcases-alongside-customers-and-launches-10-industry-solutions-with-partners Wed, 05 Mar 2025 06:00:18 -0500 spectro https://spypharm.com/mwc-barcelona-2025-maximizing-5g-network-value-in-the-age-of-ai https://spypharm.com/mwc-barcelona-2025-maximizing-5g-network-value-in-the-age-of-ai Wed, 05 Mar 2025 06:00:17 -0500 spectro https://spypharm.com/fda-approves-beigenes-tevimbra-plus-chemo-for-oesophageal-cancer https://spypharm.com/fda-approves-beigenes-tevimbra-plus-chemo-for-oesophageal-cancer Wed, 05 Mar 2025 06:00:17 -0500 spectro https://spypharm.com/antibody-drug-conjugates-tackling-the-unsolved-challenges-with-novel-technologies https://spypharm.com/antibody-drug-conjugates-tackling-the-unsolved-challenges-with-novel-technologies Wed, 05 Mar 2025 06:00:17 -0500 spectro https://spypharm.com/magnet-biomedicine-and-lilly-link-for-molecular-glue-therapeutics https://spypharm.com/magnet-biomedicine-and-lilly-link-for-molecular-glue-therapeutics Mon, 03 Mar 2025 06:00:15 -0500 spectro https://spypharm.com/new-eu-trial-regulations-could-expedite-approvals-and-address-shortages https://spypharm.com/new-eu-trial-regulations-could-expedite-approvals-and-address-shortages Sat, 01 Mar 2025 06:00:17 -0500 spectro https://spypharm.com/chmp-recommends-abbvies-rinvoq-be-approved-for-adult-gca https://spypharm.com/chmp-recommends-abbvies-rinvoq-be-approved-for-adult-gca Sat, 01 Mar 2025 06:00:16 -0500 spectro https://spypharm.com/medigene-and-epimab-to-develop-t-cell-engagers-for-solid-tumours https://spypharm.com/medigene-and-epimab-to-develop-t-cell-engagers-for-solid-tumours Sat, 01 Mar 2025 06:00:16 -0500 spectro https://spypharm.com/why-pharma-is-still-far-from-a-treatment-for-galactosemia https://spypharm.com/why-pharma-is-still-far-from-a-treatment-for-galactosemia Sat, 01 Mar 2025 06:00:16 -0500 spectro https://spypharm.com/fda-accepts-sobis-gamifant-application-for-hlhmas-treatment https://spypharm.com/fda-accepts-sobis-gamifant-application-for-hlhmas-treatment Sat, 01 Mar 2025 06:00:16 -0500 spectro https://spypharm.com/zevra-sells-priority-review-voucher-for-150m-to-support-drug-launches https://spypharm.com/zevra-sells-priority-review-voucher-for-150m-to-support-drug-launches Sat, 01 Mar 2025 06:00:16 -0500 spectro https://spypharm.com/inborn-errors-of-metabolism-elicit-unique-challenges-for-therapy-development https://spypharm.com/inborn-errors-of-metabolism-elicit-unique-challenges-for-therapy-development Sat, 01 Mar 2025 06:00:16 -0500 spectro https://spypharm.com/rare-disease-treatments-skipping-uk-patients-largely-due-to-costs-survey-shows https://spypharm.com/rare-disease-treatments-skipping-uk-patients-largely-due-to-costs-survey-shows Sat, 01 Mar 2025 06:00:16 -0500 spectro https://spypharm.com/exelixis-focuses-on-future-growth-despite-cosmic-313-trial-challenges https://spypharm.com/exelixis-focuses-on-future-growth-despite-cosmic-313-trial-challenges Sat, 01 Mar 2025 06:00:16 -0500 spectro https://spypharm.com/alltrna-plans-to-tackle-rare-diseases-using-trna-based-therapies https://spypharm.com/alltrna-plans-to-tackle-rare-diseases-using-trna-based-therapies Sat, 01 Mar 2025 06:00:16 -0500 spectro https://spypharm.com/redhill-and-hyloris-sign-agreement-for-bekindas-development https://spypharm.com/redhill-and-hyloris-sign-agreement-for-bekindas-development Thu, 27 Feb 2025 06:00:17 -0500 spectro https://spypharm.com/eli-lilly-pays-10m-upfront-for-organovos-fxr-agonist https://spypharm.com/eli-lilly-pays-10m-upfront-for-organovos-fxr-agonist Thu, 27 Feb 2025 06:00:17 -0500 spectro https://spypharm.com/fda-grants-breakthrough-status-to-grin-therapeutics-radiprodil https://spypharm.com/fda-grants-breakthrough-status-to-grin-therapeutics-radiprodil Thu, 27 Feb 2025 06:00:17 -0500 spectro https://spypharm.com/fda-grants-fast-track-status-to-pyxis-pyx-201 https://spypharm.com/fda-grants-fast-track-status-to-pyxis-pyx-201 Thu, 27 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/eli-lilly-to-expand-us-pharma-manufacturing-with-four-new-sites https://spypharm.com/eli-lilly-to-expand-us-pharma-manufacturing-with-four-new-sites Thu, 27 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/magazine-radiopharmaceutical-deals-drive-sector-growth-despite-supplycrisis https://spypharm.com/magazine-radiopharmaceutical-deals-drive-sector-growth-despite-supplycrisis Thu, 27 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/eikon-raises-almost-351m-to-advance-cancer-candidates-through-the-clinic https://spypharm.com/eikon-raises-almost-351m-to-advance-cancer-candidates-through-the-clinic Thu, 27 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/emalex-eyes-fda-approval-for-tourette-syndrome-therapy-after-phase-iii-success https://spypharm.com/emalex-eyes-fda-approval-for-tourette-syndrome-therapy-after-phase-iii-success Thu, 27 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/idorsias-tryvio-deal-collapses-forcing-company-to-find-cash-urgently https://spypharm.com/idorsias-tryvio-deal-collapses-forcing-company-to-find-cash-urgently Thu, 27 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/fda-approvals-decline-but-drug-innovation-remains-strong-even-among-small-sponsors https://spypharm.com/fda-approvals-decline-but-drug-innovation-remains-strong-even-among-small-sponsors Thu, 27 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/teva-and-alvotech-launch-ustekinumab-biosimilar-injection-in-us https://spypharm.com/teva-and-alvotech-launch-ustekinumab-biosimilar-injection-in-us Tue, 25 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/fda-approves-mirums-ctexli-for-cerebrotendinous-xanthomatosis https://spypharm.com/fda-approves-mirums-ctexli-for-cerebrotendinous-xanthomatosis Tue, 25 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/meiragtx-seeks-uk-approval-after-gene-therapy-restores-sight-in-children-born-blind https://spypharm.com/meiragtx-seeks-uk-approval-after-gene-therapy-restores-sight-in-children-born-blind Tue, 25 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/fda-accepts-bms-opdivo-yervoy-combo-sbla-for-colorectal-cancer https://spypharm.com/fda-accepts-bms-opdivo-yervoy-combo-sbla-for-colorectal-cancer Tue, 25 Feb 2025 06:00:15 -0500 spectro https://spypharm.com/ec-authorises-celltrions-avtozma-for-multiple-indications https://spypharm.com/ec-authorises-celltrions-avtozma-for-multiple-indications Tue, 25 Feb 2025 06:00:15 -0500 spectro https://spypharm.com/transforming-manufacturing-and-packaging-at-pharmap-2025 https://spypharm.com/transforming-manufacturing-and-packaging-at-pharmap-2025 Tue, 25 Feb 2025 06:00:15 -0500 spectro https://spypharm.com/semaglutide-shortage-ends-as-fda-sets-deadline-for-compounders https://spypharm.com/semaglutide-shortage-ends-as-fda-sets-deadline-for-compounders Tue, 25 Feb 2025 06:00:15 -0500 spectro https://spypharm.com/sionna-therapeutics-ipo-a-strategic-shift-in-the-cystic-fibrosis-market https://spypharm.com/sionna-therapeutics-ipo-a-strategic-shift-in-the-cystic-fibrosis-market Tue, 25 Feb 2025 06:00:15 -0500 spectro https://spypharm.com/pfizer-sets-sights-on-summits-bispecific-in-combo-with-its-adcs https://spypharm.com/pfizer-sets-sights-on-summits-bispecific-in-combo-with-its-adcs Tue, 25 Feb 2025 06:00:15 -0500 spectro https://spypharm.com/how-cns-researchers-are-handling-clinical-trial-turbulence https://spypharm.com/how-cns-researchers-are-handling-clinical-trial-turbulence Sun, 23 Feb 2025 06:00:10 -0500 spectro https://spypharm.com/nice-green-lights-two-blood-cancer-therapies-for-nhs-use https://spypharm.com/nice-green-lights-two-blood-cancer-therapies-for-nhs-use Sun, 23 Feb 2025 06:00:10 -0500 spectro https://spypharm.com/incyte-and-genesis-collaborate-on-small-molecule-medicines https://spypharm.com/incyte-and-genesis-collaborate-on-small-molecule-medicines Sun, 23 Feb 2025 06:00:10 -0500 spectro https://spypharm.com/navigating-the-complexities-of-sustainable-specialty-pharma-supply-chains https://spypharm.com/navigating-the-complexities-of-sustainable-specialty-pharma-supply-chains Sun, 23 Feb 2025 06:00:10 -0500 spectro https://spypharm.com/struggling-bluebird-bio-to-go-private-for-less-than-30m https://spypharm.com/struggling-bluebird-bio-to-go-private-for-less-than-30m Sun, 23 Feb 2025 06:00:09 -0500 spectro https://spypharm.com/pfizer-shelves-haemophilia-gene-therapy-beqvez-amid-low-demand https://spypharm.com/pfizer-shelves-haemophilia-gene-therapy-beqvez-amid-low-demand Sun, 23 Feb 2025 06:00:09 -0500 spectro https://spypharm.com/urogen-acquires-iconovirs-oncolytic-virus-assets https://spypharm.com/urogen-acquires-iconovirs-oncolytic-virus-assets Sun, 23 Feb 2025 06:00:09 -0500 spectro https://spypharm.com/glp-1-receptor-agonists-could-hold-promise-for-opioid-use-disorder-treatment https://spypharm.com/glp-1-receptor-agonists-could-hold-promise-for-opioid-use-disorder-treatment Sun, 23 Feb 2025 06:00:09 -0500 spectro https://spypharm.com/fibrogen-sells-china-unit-to-astrazeneca-for-160m https://spypharm.com/fibrogen-sells-china-unit-to-astrazeneca-for-160m Fri, 21 Feb 2025 06:00:17 -0500 spectro https://spypharm.com/x4-and-taiba-to-distribute-whim-syndrome-therapy-in-middle-east https://spypharm.com/x4-and-taiba-to-distribute-whim-syndrome-therapy-in-middle-east Fri, 21 Feb 2025 06:00:17 -0500 spectro https://spypharm.com/key-pharma-launch-trends-in-2024 https://spypharm.com/key-pharma-launch-trends-in-2024 Fri, 21 Feb 2025 06:00:17 -0500 spectro https://spypharm.com/fda-authorises-immunitybios-bcg-alternative-to-treat-bladder-cancer https://spypharm.com/fda-authorises-immunitybios-bcg-alternative-to-treat-bladder-cancer Fri, 21 Feb 2025 06:00:17 -0500 spectro https://spypharm.com/pharma-and-medtech-industry-reacts-to-fda-cdc-and-nih-job-cuts https://spypharm.com/pharma-and-medtech-industry-reacts-to-fda-cdc-and-nih-job-cuts Fri, 21 Feb 2025 06:00:17 -0500 spectro https://spypharm.com/fda-grants-priority-review-for-boehringers-zongertinib-nda-in-nsclc https://spypharm.com/fda-grants-priority-review-for-boehringers-zongertinib-nda-in-nsclc Fri, 21 Feb 2025 06:00:17 -0500 spectro https://spypharm.com/zealand-pharma-steadfastly-upholds-amylin-based-obesity-drug-strategy https://spypharm.com/zealand-pharma-steadfastly-upholds-amylin-based-obesity-drug-strategy Fri, 21 Feb 2025 06:00:17 -0500 spectro https://spypharm.com/who-targets-over-half-a-million-children-in-gaza-for-polio-vaccine-drive https://spypharm.com/who-targets-over-half-a-million-children-in-gaza-for-polio-vaccine-drive Fri, 21 Feb 2025 06:00:17 -0500 spectro https://spypharm.com/scientists-develop-largest-ever-biological-ai-model-that-thinks-in-nucleotides https://spypharm.com/scientists-develop-largest-ever-biological-ai-model-that-thinks-in-nucleotides Fri, 21 Feb 2025 06:00:17 -0500 spectro https://spypharm.com/japans-mhlw-approves-csl-behrings-andembry-to-stop-hae-attacks https://spypharm.com/japans-mhlw-approves-csl-behrings-andembry-to-stop-hae-attacks Fri, 21 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/fda-grants-fast-track-status-to-rznomics-rz-001-for-hcc https://spypharm.com/fda-grants-fast-track-status-to-rznomics-rz-001-for-hcc Wed, 19 Feb 2025 06:00:17 -0500 spectro https://spypharm.com/onos-tgct-therapy-wins-fda-approval-challenging-daiichi-sankyo https://spypharm.com/onos-tgct-therapy-wins-fda-approval-challenging-daiichi-sankyo Wed, 19 Feb 2025 06:00:17 -0500 spectro https://spypharm.com/fda-to-review-sanofi-and-regenerons-dupixent-sbla-for-bullous-pemphigoid https://spypharm.com/fda-to-review-sanofi-and-regenerons-dupixent-sbla-for-bullous-pemphigoid Wed, 19 Feb 2025 06:00:17 -0500 spectro https://spypharm.com/hmri-and-novartis-australia-sign-mou-to-expedite-medical-research https://spypharm.com/hmri-and-novartis-australia-sign-mou-to-expedite-medical-research Wed, 19 Feb 2025 06:00:17 -0500 spectro https://spypharm.com/oncology-and-eclinical-solutions-how-one-company-is-adapting-to-the-challenges https://spypharm.com/oncology-and-eclinical-solutions-how-one-company-is-adapting-to-the-challenges Wed, 19 Feb 2025 06:00:17 -0500 spectro https://spypharm.com/new-ceos-to-join-merck-kgaas-executive-board https://spypharm.com/new-ceos-to-join-merck-kgaas-executive-board Wed, 19 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/gileads-lenacapavir-moves-closer-to-fda-approval-for-hiv-prep-use https://spypharm.com/gileads-lenacapavir-moves-closer-to-fda-approval-for-hiv-prep-use Wed, 19 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/valneva-hits-2024-sales-target-but-plans-lower-cash-burn-in-2025 https://spypharm.com/valneva-hits-2024-sales-target-but-plans-lower-cash-burn-in-2025 Wed, 19 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/ec-conditionally-approves-msds-welireg-for-vhl-disease-and-rcc https://spypharm.com/ec-conditionally-approves-msds-welireg-for-vhl-disease-and-rcc Wed, 19 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/can-innovation-in-clinical-trial-delivery-meet-the-demands-of-increasing-complexity-in-drug-development https://spypharm.com/can-innovation-in-clinical-trial-delivery-meet-the-demands-of-increasing-complexity-in-drug-development Wed, 19 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/moderna-reports-decline-in-q4-2024-revenue https://spypharm.com/moderna-reports-decline-in-q4-2024-revenue Mon, 17 Feb 2025 06:00:13 -0500 spectro https://spypharm.com/revolutionary-approaches-to-drug-design-how-ai-is-transforming-life-sciences https://spypharm.com/revolutionary-approaches-to-drug-design-how-ai-is-transforming-life-sciences Sat, 15 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/aardvark-prices-942m-ipo-to-fund-development-of-prader-willi-syndrome-drug https://spypharm.com/aardvark-prices-942m-ipo-to-fund-development-of-prader-willi-syndrome-drug Sat, 15 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/trump-presidency-signals-potential-downturn-in-nih-sbirsttr-grant-funding-for-biopharma-drugs https://spypharm.com/trump-presidency-signals-potential-downturn-in-nih-sbirsttr-grant-funding-for-biopharma-drugs Sat, 15 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/smartcella-gains-rights-to-advance-cell-therapy-research-for-parkinsons https://spypharm.com/smartcella-gains-rights-to-advance-cell-therapy-research-for-parkinsons Sat, 15 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/ec-approves-csls-andembry-to-stop-hereditary-angioedema-attacks https://spypharm.com/ec-approves-csls-andembry-to-stop-hereditary-angioedema-attacks Sat, 15 Feb 2025 06:00:15 -0500 spectro https://spypharm.com/eu-reshapes-htas-is-the-industry-ready-for-it https://spypharm.com/eu-reshapes-htas-is-the-industry-ready-for-it Sat, 15 Feb 2025 06:00:15 -0500 spectro https://spypharm.com/newleos-secures-935m-for-neuropsychiatric-treatments https://spypharm.com/newleos-secures-935m-for-neuropsychiatric-treatments Sat, 15 Feb 2025 06:00:15 -0500 spectro https://spypharm.com/dmd-market-expected-to-grow-to-52bn-in-the-7mm-by-2033 https://spypharm.com/dmd-market-expected-to-grow-to-52bn-in-the-7mm-by-2033 Sat, 15 Feb 2025 06:00:15 -0500 spectro https://spypharm.com/galderma-enters-fierce-european-atopic-dermatitis-market-with-nemluvio-approval https://spypharm.com/galderma-enters-fierce-european-atopic-dermatitis-market-with-nemluvio-approval Sat, 15 Feb 2025 06:00:15 -0500 spectro https://spypharm.com/health-canada-approves-novartis-fabhalta-for-pnh-with-haemolytic-anaemia https://spypharm.com/health-canada-approves-novartis-fabhalta-for-pnh-with-haemolytic-anaemia Sat, 15 Feb 2025 06:00:15 -0500 spectro https://spypharm.com/abbvie-and-xilio-to-collaborate-on-antibody-based-immunotherapies https://spypharm.com/abbvie-and-xilio-to-collaborate-on-antibody-based-immunotherapies Thu, 13 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/oct-west-coast-2025-china-surpasses-us-for-annual-number-of-clinical-trials https://spypharm.com/oct-west-coast-2025-china-surpasses-us-for-annual-number-of-clinical-trials Thu, 13 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/lundbeck-gains-fda-fast-track-designation-for-msa-therapy-amlenetug https://spypharm.com/lundbeck-gains-fda-fast-track-designation-for-msa-therapy-amlenetug Thu, 13 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/fda-approves-gomekli-as-first-neurofibromatosis-drug-for-adults https://spypharm.com/fda-approves-gomekli-as-first-neurofibromatosis-drug-for-adults Thu, 13 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/travere-takes-rare-disease-kidney-drug-to-fda-despite-failed-trial https://spypharm.com/travere-takes-rare-disease-kidney-drug-to-fda-despite-failed-trial Thu, 13 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/ec-grants-marketing-authorisation-to-bridgebios-attr-cm-treatment https://spypharm.com/ec-grants-marketing-authorisation-to-bridgebios-attr-cm-treatment Thu, 13 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/health-canada-approves-msds-keytruda-for-nsclc-stages https://spypharm.com/health-canada-approves-msds-keytruda-for-nsclc-stages Thu, 13 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/be-realistic-responsive-and-transparent-how-to-engage-underperforming-sites https://spypharm.com/be-realistic-responsive-and-transparent-how-to-engage-underperforming-sites Thu, 13 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/trumps-tariffs-will-trickle-down-the-clinical-trial-chain https://spypharm.com/trumps-tariffs-will-trickle-down-the-clinical-trial-chain Thu, 13 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/abcuro-secures-200m-as-it-eyes-approval-for-rare-muscle-disease-drug https://spypharm.com/abcuro-secures-200m-as-it-eyes-approval-for-rare-muscle-disease-drug Thu, 13 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/keymeds-stapokibart-approved-by-nmpa-for-seasonal-allergic-rhinitis https://spypharm.com/keymeds-stapokibart-approved-by-nmpa-for-seasonal-allergic-rhinitis Tue, 11 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/fourth-person-receives-egenesis-gene-edited-pig-kidney-transplant https://spypharm.com/fourth-person-receives-egenesis-gene-edited-pig-kidney-transplant Tue, 11 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/eton-secures-us-patent-for-diabetes-insipidus-treatment https://spypharm.com/eton-secures-us-patent-for-diabetes-insipidus-treatment Tue, 11 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/fda-approves-abbvies-emblaveo-for-intra-abdominal-infections https://spypharm.com/fda-approves-abbvies-emblaveo-for-intra-abdominal-infections Tue, 11 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/super-bowl-ad-for-copycat-weight-loss-drugs-stokes-pharma-power-debate https://spypharm.com/super-bowl-ad-for-copycat-weight-loss-drugs-stokes-pharma-power-debate Tue, 11 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/obesity-market-to-reach-1735-billion-by-2031 https://spypharm.com/obesity-market-to-reach-1735-billion-by-2031 Tue, 11 Feb 2025 06:00:15 -0500 spectro https://spypharm.com/bio-thera-signs-us-deal-with-intas-for-golimumab-biosimilar https://spypharm.com/bio-thera-signs-us-deal-with-intas-for-golimumab-biosimilar Tue, 11 Feb 2025 06:00:15 -0500 spectro https://spypharm.com/boehringer-seeks-approval-of-lung-disease-drug-after-second-phase-iii-success https://spypharm.com/boehringer-seeks-approval-of-lung-disease-drug-after-second-phase-iii-success Tue, 11 Feb 2025 06:00:15 -0500 spectro https://spypharm.com/public-health-strategies-skip-patients-with-rare-diseases-says-uk-study https://spypharm.com/public-health-strategies-skip-patients-with-rare-diseases-says-uk-study Tue, 11 Feb 2025 06:00:15 -0500 spectro https://spypharm.com/treating-alcohol-addiction-filling-the-medication-gap https://spypharm.com/treating-alcohol-addiction-filling-the-medication-gap Sun, 09 Feb 2025 06:00:11 -0500 spectro https://spypharm.com/relmada-acquires-tourettes-therapy-rights-from-asarina https://spypharm.com/relmada-acquires-tourettes-therapy-rights-from-asarina Sun, 09 Feb 2025 06:00:10 -0500 spectro https://spypharm.com/bain-capital-buys-mitsubishi-tanabe-pharma-for-33bn https://spypharm.com/bain-capital-buys-mitsubishi-tanabe-pharma-for-33bn Sun, 09 Feb 2025 06:00:09 -0500 spectro https://spypharm.com/sanofi-increases-ownership-stake-partaking-in-pharma-buyback-trend https://spypharm.com/sanofi-increases-ownership-stake-partaking-in-pharma-buyback-trend Sun, 09 Feb 2025 06:00:09 -0500 spectro https://spypharm.com/alumis-and-acelyrin-sign-merger-agreement https://spypharm.com/alumis-and-acelyrin-sign-merger-agreement Sun, 09 Feb 2025 06:00:09 -0500 spectro https://spypharm.com/43rd-annual-jp-morgan-healthcare-conference-2025-or https://spypharm.com/43rd-annual-jp-morgan-healthcare-conference-2025-or Sun, 09 Feb 2025 06:00:09 -0500 spectro https://spypharm.com/genentech-eyes-lupus-market-for-gazyva-with-positive-phase-iii-data-readout https://spypharm.com/genentech-eyes-lupus-market-for-gazyva-with-positive-phase-iii-data-readout Sun, 09 Feb 2025 06:00:09 -0500 spectro https://spypharm.com/how-ai-is-streamlining-cell-and-gene-therapy-manufacturing https://spypharm.com/how-ai-is-streamlining-cell-and-gene-therapy-manufacturing Sun, 09 Feb 2025 06:00:09 -0500 spectro https://spypharm.com/impact-of-proposed-us-tariffs-on-pharmaceutical-fdi-in-canada-mexico-china-and-europe https://spypharm.com/impact-of-proposed-us-tariffs-on-pharmaceutical-fdi-in-canada-mexico-china-and-europe Sun, 09 Feb 2025 06:00:09 -0500 spectro https://spypharm.com/dr-reddys-and-shanghai-henlius-sign-agreement-for-hlx15 https://spypharm.com/dr-reddys-and-shanghai-henlius-sign-agreement-for-hlx15 Fri, 07 Feb 2025 06:00:20 -0500 spectro https://spypharm.com/astrazenecas-shares-rise-as-it-addresses-china-investigation https://spypharm.com/astrazenecas-shares-rise-as-it-addresses-china-investigation Fri, 07 Feb 2025 06:00:20 -0500 spectro https://spypharm.com/fda-grants-orphan-drug-status-to-arbor-biotechnologies-ph1 https://spypharm.com/fda-grants-orphan-drug-status-to-arbor-biotechnologies-ph1 Fri, 07 Feb 2025 06:00:20 -0500 spectro https://spypharm.com/supernus-wins-fda-approval-for-parkinsons-pump-on-fourth-try https://spypharm.com/supernus-wins-fda-approval-for-parkinsons-pump-on-fourth-try Fri, 07 Feb 2025 06:00:20 -0500 spectro https://spypharm.com/tripartite-mou-signed-for-mrna-production-platform-in-egypt https://spypharm.com/tripartite-mou-signed-for-mrna-production-platform-in-egypt Fri, 07 Feb 2025 06:00:20 -0500 spectro https://spypharm.com/uspto-grants-patent-to-vistagens-neuropathic-pain-treatment https://spypharm.com/uspto-grants-patent-to-vistagens-neuropathic-pain-treatment Fri, 07 Feb 2025 06:00:20 -0500 spectro https://spypharm.com/x-elio-partners-with-pharmaceutical-programme-for-10-year-solar-ppa https://spypharm.com/x-elio-partners-with-pharmaceutical-programme-for-10-year-solar-ppa Fri, 07 Feb 2025 06:00:20 -0500 spectro https://spypharm.com/valnevas-chikungunya-vaccine-wins-uk-approval https://spypharm.com/valnevas-chikungunya-vaccine-wins-uk-approval Fri, 07 Feb 2025 06:00:20 -0500 spectro https://spypharm.com/novo-nordisk-plans-new-study-for-cagrisema-targets-2026-submission https://spypharm.com/novo-nordisk-plans-new-study-for-cagrisema-targets-2026-submission Fri, 07 Feb 2025 06:00:20 -0500 spectro https://spypharm.com/supply-chains-and-ai-take-precedence-at-european-clinical-trial-meeting https://spypharm.com/supply-chains-and-ai-take-precedence-at-european-clinical-trial-meeting Fri, 07 Feb 2025 06:00:20 -0500 spectro https://spypharm.com/microplastics-the-silent-threat https://spypharm.com/microplastics-the-silent-threat Wed, 05 Feb 2025 06:00:24 -0500 spectro https://spypharm.com/medpharm-appoints-bill-humphries-as-new-ceo https://spypharm.com/medpharm-appoints-bill-humphries-as-new-ceo Wed, 05 Feb 2025 06:00:23 -0500 spectro https://spypharm.com/jabil-acquires-cdmo-pii-to-support-drug-development-customers https://spypharm.com/jabil-acquires-cdmo-pii-to-support-drug-development-customers Wed, 05 Feb 2025 06:00:23 -0500 spectro https://spypharm.com/italian-charity-seeks-ema-approval-for-rescued-gene-therapy https://spypharm.com/italian-charity-seeks-ema-approval-for-rescued-gene-therapy Wed, 05 Feb 2025 06:00:23 -0500 spectro https://spypharm.com/usc-receives-grant-for-gene-therapy-targeting-glioblastoma https://spypharm.com/usc-receives-grant-for-gene-therapy-targeting-glioblastoma Wed, 05 Feb 2025 06:00:23 -0500 spectro https://spypharm.com/immunotherapeutic-responses-and-their-assessments https://spypharm.com/immunotherapeutic-responses-and-their-assessments Wed, 05 Feb 2025 06:00:23 -0500 spectro https://spypharm.com/world-cancer-day-who-warns-of-rising-cancer-burden-in-southeast-asia https://spypharm.com/world-cancer-day-who-warns-of-rising-cancer-burden-in-southeast-asia Wed, 05 Feb 2025 06:00:23 -0500 spectro https://spypharm.com/radiopharmaceutical-deals-drive-sector-growth-despite-supply-crisis https://spypharm.com/radiopharmaceutical-deals-drive-sector-growth-despite-supply-crisis Wed, 05 Feb 2025 06:00:23 -0500 spectro https://spypharm.com/thermo-fisher-continues-viral-vector-withdrawal-lays-off-300-employees https://spypharm.com/thermo-fisher-continues-viral-vector-withdrawal-lays-off-300-employees Wed, 05 Feb 2025 06:00:23 -0500 spectro https://spypharm.com/vanda-and-anaptysbio-link-for-generalised-pustular-psoriasis-therapy https://spypharm.com/vanda-and-anaptysbio-link-for-generalised-pustular-psoriasis-therapy Wed, 05 Feb 2025 06:00:23 -0500 spectro https://spypharm.com/viiv-healthcare-and-jjs-adolescent-hiv-1-combo-gains-ec-authorisation https://spypharm.com/viiv-healthcare-and-jjs-adolescent-hiv-1-combo-gains-ec-authorisation Mon, 03 Feb 2025 06:00:15 -0500 spectro https://spypharm.com/fda-approves-vertexs-acute-pain-treatment-journavx https://spypharm.com/fda-approves-vertexs-acute-pain-treatment-journavx Sat, 01 Feb 2025 06:00:17 -0500 spectro https://spypharm.com/rfk-jr-thrusts-domestic-manufacturing-agenda-on-day-2-of-confirmation-hearings https://spypharm.com/rfk-jr-thrusts-domestic-manufacturing-agenda-on-day-2-of-confirmation-hearings Sat, 01 Feb 2025 06:00:17 -0500 spectro https://spypharm.com/ema-recommends-bavarian-nordics-chikungunya-vaccine-for-adults-and-teenagers https://spypharm.com/ema-recommends-bavarian-nordics-chikungunya-vaccine-for-adults-and-teenagers Sat, 01 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/rentschler-closes-uk-cell-and-gene-therapy-facility-and-does-a-pivot-to-biologics https://spypharm.com/rentschler-closes-uk-cell-and-gene-therapy-facility-and-does-a-pivot-to-biologics Sat, 01 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/roche-targets-continued-growth-after-strong-2024-sales https://spypharm.com/roche-targets-continued-growth-after-strong-2024-sales Sat, 01 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/all-change-in-germany-confidential-pricing-in-irp-out https://spypharm.com/all-change-in-germany-confidential-pricing-in-irp-out Sat, 01 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/sanofi-reports-q4-2024-increase-in-net-income-to-916m https://spypharm.com/sanofi-reports-q4-2024-increase-in-net-income-to-916m Sat, 01 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/nhs-england-to-offer-casgevy-for-sickle-cell-disease-patients https://spypharm.com/nhs-england-to-offer-casgevy-for-sickle-cell-disease-patients Sat, 01 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/hiroyuki-okuzawa-succeeds-sunao-manabe-as-daiichi-sankyo-ceo https://spypharm.com/hiroyuki-okuzawa-succeeds-sunao-manabe-as-daiichi-sankyo-ceo Sat, 01 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/top-20-biopharma-companies-market-caps-rise-17-over-2024-amid-policy https://spypharm.com/top-20-biopharma-companies-market-caps-rise-17-over-2024-amid-policy Sat, 01 Feb 2025 06:00:16 -0500 spectro https://spypharm.com/will-european-pfas-ban-disrupt-pharma-supply-chains https://spypharm.com/will-european-pfas-ban-disrupt-pharma-supply-chains Thu, 30 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/fda-gives-rmat-designation-to-beacons-retinitis-pigmentosa-treatment https://spypharm.com/fda-gives-rmat-designation-to-beacons-retinitis-pigmentosa-treatment Thu, 30 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/allakos-cuts-75-of-workforce-after-chronic-hives-trial-failure https://spypharm.com/allakos-cuts-75-of-workforce-after-chronic-hives-trial-failure Thu, 30 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/acellera-and-psivant-partner-for-ai-driven-drug-discovery https://spypharm.com/acellera-and-psivant-partner-for-ai-driven-drug-discovery Thu, 30 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/lyndra-therapeutics-appoints-adam-sayer-new-ceo-and-president https://spypharm.com/lyndra-therapeutics-appoints-adam-sayer-new-ceo-and-president Thu, 30 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/lantheus-acquires-radiopharma-cdmo-evergreen-for-up-to-1bn https://spypharm.com/lantheus-acquires-radiopharma-cdmo-evergreen-for-up-to-1bn Thu, 30 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/novo-nordisk-secures-fda-approval-for-ozempic-in-diabetes-with-ckd https://spypharm.com/novo-nordisk-secures-fda-approval-for-ozempic-in-diabetes-with-ckd Thu, 30 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/sonnet-biotherapeutics-secures-eu-patent-for-fhab-technology https://spypharm.com/sonnet-biotherapeutics-secures-eu-patent-for-fhab-technology Thu, 30 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/rfk-jr-denies-being-anti-vaccine-during-intense-senate-confirmation https://spypharm.com/rfk-jr-denies-being-anti-vaccine-during-intense-senate-confirmation Thu, 30 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/fda-expands-enhertu-approval-to-include-her2-ultralow-breast-cancer-patients https://spypharm.com/fda-expands-enhertu-approval-to-include-her2-ultralow-breast-cancer-patients Thu, 30 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/eisai-and-biogens-leqembi-sbla-set-for-alzheimers-maintenance-dosing https://spypharm.com/eisai-and-biogens-leqembi-sbla-set-for-alzheimers-maintenance-dosing Tue, 28 Jan 2025 06:00:11 -0500 spectro https://spypharm.com/trying-times-for-biopharmaceuticals-how-researchers-can-flourish-amid-industry-challenges https://spypharm.com/trying-times-for-biopharmaceuticals-how-researchers-can-flourish-amid-industry-challenges Tue, 28 Jan 2025 06:00:11 -0500 spectro https://spypharm.com/ai-driven-virtual-cgm-data-boosts-understanding-of-t1d-risks https://spypharm.com/ai-driven-virtual-cgm-data-boosts-understanding-of-t1d-risks Tue, 28 Jan 2025 06:00:10 -0500 spectro https://spypharm.com/gsk-and-university-of-oxford-partner-for-cancer-vaccine-research https://spypharm.com/gsk-and-university-of-oxford-partner-for-cancer-vaccine-research Tue, 28 Jan 2025 06:00:10 -0500 spectro https://spypharm.com/pfizer-settles-biohaven-kickback-claims-case-for-597m https://spypharm.com/pfizer-settles-biohaven-kickback-claims-case-for-597m Tue, 28 Jan 2025 06:00:10 -0500 spectro https://spypharm.com/msd-wins-fda-priority-review-for-welireg-in-rare-endocrine-cancer https://spypharm.com/msd-wins-fda-priority-review-for-welireg-in-rare-endocrine-cancer Tue, 28 Jan 2025 06:00:10 -0500 spectro https://spypharm.com/the-ai-advantage-in-discovering-new-medicines https://spypharm.com/the-ai-advantage-in-discovering-new-medicines Tue, 28 Jan 2025 06:00:10 -0500 spectro https://spypharm.com/bia-report-uk-biotech-investment-surged-to-35bn-in-2024 https://spypharm.com/bia-report-uk-biotech-investment-surged-to-35bn-in-2024 Tue, 28 Jan 2025 06:00:10 -0500 spectro https://spypharm.com/tevogen-bio-and-microsoft-expand-ai-collaboration-to-predictcell-tech https://spypharm.com/tevogen-bio-and-microsoft-expand-ai-collaboration-to-predictcell-tech Tue, 28 Jan 2025 06:00:10 -0500 spectro https://spypharm.com/ascentage-pharma-raises-126m-in-first-biotech-ipo-of-2025 https://spypharm.com/ascentage-pharma-raises-126m-in-first-biotech-ipo-of-2025 Sun, 26 Jan 2025 06:00:12 -0500 spectro https://spypharm.com/purdue-and-sackler-family-agree-to-74bn-national-opioid-settlement https://spypharm.com/purdue-and-sackler-family-agree-to-74bn-national-opioid-settlement Sun, 26 Jan 2025 06:00:12 -0500 spectro https://spypharm.com/fda-approves-drug-application-for-lupins-heart-failure-therapy https://spypharm.com/fda-approves-drug-application-for-lupins-heart-failure-therapy Sun, 26 Jan 2025 06:00:12 -0500 spectro https://spypharm.com/podcast-adaptive-logistics-in-a-changing-clinical-landscape https://spypharm.com/podcast-adaptive-logistics-in-a-changing-clinical-landscape Sun, 26 Jan 2025 06:00:12 -0500 spectro https://spypharm.com/stealth-faces-another-hurdle-as-fda-delays-decision-on-barth-syndrome-drug https://spypharm.com/stealth-faces-another-hurdle-as-fda-delays-decision-on-barth-syndrome-drug Sun, 26 Jan 2025 06:00:12 -0500 spectro https://spypharm.com/fda-adds-boxed-warning-to-multiple-sclerosis-drugs-after-anaphylaxis-cases https://spypharm.com/fda-adds-boxed-warning-to-multiple-sclerosis-drugs-after-anaphylaxis-cases Fri, 24 Jan 2025 06:00:17 -0500 spectro https://spypharm.com/disc-raises-2255m-as-it-eyes-approval-of-rare-skin-disorder-drug https://spypharm.com/disc-raises-2255m-as-it-eyes-approval-of-rare-skin-disorder-drug Fri, 24 Jan 2025 06:00:17 -0500 spectro https://spypharm.com/emcure-pharmaceuticals-opens-new-rd-centre-in-gujarat-india https://spypharm.com/emcure-pharmaceuticals-opens-new-rd-centre-in-gujarat-india Fri, 24 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/abbvie-and-neomorph-link-on-oncologyimmunology-glue-degraders https://spypharm.com/abbvie-and-neomorph-link-on-oncologyimmunology-glue-degraders Fri, 24 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/bladder-cancer-shaping-the-future-of-global-clinical-trials https://spypharm.com/bladder-cancer-shaping-the-future-of-global-clinical-trials Fri, 24 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/fda-grants-odd-status-to-zai-labs-lung-cancer-treatment https://spypharm.com/fda-grants-odd-status-to-zai-labs-lung-cancer-treatment Fri, 24 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-winners-announced https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-winners-announced Fri, 24 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/magazine-the-biggest-challenges-clinical-trials-will-face-in-2025 https://spypharm.com/magazine-the-biggest-challenges-clinical-trials-will-face-in-2025 Fri, 24 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/biogens-higher-dose-spinraza-under-review-by-us-and-eu-regulators https://spypharm.com/biogens-higher-dose-spinraza-under-review-by-us-and-eu-regulators Fri, 24 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/emergent-seeking-to-reverse-fortunes-and-become-a-major-overdose-treatment-player https://spypharm.com/emergent-seeking-to-reverse-fortunes-and-become-a-major-overdose-treatment-player Fri, 24 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/junshi-partners-leo-pharma-for-toripalimab-distribution-in-europe https://spypharm.com/junshi-partners-leo-pharma-for-toripalimab-distribution-in-europe Wed, 22 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/jjs-lazcluzerybrevant-combination-obtains-european-approval-to-treat-nsclc https://spypharm.com/jjs-lazcluzerybrevant-combination-obtains-european-approval-to-treat-nsclc Wed, 22 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/active-pharmaceutical-ingredients-and-intermediates-for-the-pharmaceutical-industry https://spypharm.com/active-pharmaceutical-ingredients-and-intermediates-for-the-pharmaceutical-industry Wed, 22 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/cepi-provides-62m-to-push-first-mrna-based-rift-valley-fever-vaccine-into-trial https://spypharm.com/cepi-provides-62m-to-push-first-mrna-based-rift-valley-fever-vaccine-into-trial Wed, 22 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/fda-breakthrough-status-for-bluejays-chd-therapy-brelovitug https://spypharm.com/fda-breakthrough-status-for-bluejays-chd-therapy-brelovitug Wed, 22 Jan 2025 06:00:17 -0500 spectro https://spypharm.com/catalent-backs-decentralised-manufacture-of-galapagos-car-t-therapy https://spypharm.com/catalent-backs-decentralised-manufacture-of-galapagos-car-t-therapy Wed, 22 Jan 2025 06:00:17 -0500 spectro https://spypharm.com/nvidia-champions-innophore-partnership-to-model-drug-dynamics-with-ai https://spypharm.com/nvidia-champions-innophore-partnership-to-model-drug-dynamics-with-ai Wed, 22 Jan 2025 06:00:17 -0500 spectro https://spypharm.com/ais-potential-in-the-womens-health-exciting-says-gates-foundation-leader https://spypharm.com/ais-potential-in-the-womens-health-exciting-says-gates-foundation-leader Wed, 22 Jan 2025 06:00:17 -0500 spectro https://spypharm.com/key-lead-generation-providers-and-technology-solutions-for-the-pharmaceutical-industry https://spypharm.com/key-lead-generation-providers-and-technology-solutions-for-the-pharmaceutical-industry Wed, 22 Jan 2025 06:00:17 -0500 spectro https://spypharm.com/fda-approves-amgens-combo-therapy-for-colorectal-cancer https://spypharm.com/fda-approves-amgens-combo-therapy-for-colorectal-cancer Mon, 20 Jan 2025 06:00:11 -0500 spectro https://spypharm.com/leading-sales-and-marketing-intent-data-database-and-data-enrichment-providers-and-technology-solutions-for-the-pharmaceutical-industry https://spypharm.com/leading-sales-and-marketing-intent-data-database-and-data-enrichment-providers-and-technology-solutions-for-the-pharmaceutical-industry Mon, 20 Jan 2025 06:00:11 -0500 spectro https://spypharm.com/novo-nordisks-ozempic-named-in-latest-medicare-price-negotiations https://spypharm.com/novo-nordisks-ozempic-named-in-latest-medicare-price-negotiations Sat, 18 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/fda-beats-ema-to-most-approved-new-drugs-in-2024 https://spypharm.com/fda-beats-ema-to-most-approved-new-drugs-in-2024 Sat, 18 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/pfizer-believes-in-the-metaverse-will-healthcare-thaw-the-technologys-winter https://spypharm.com/pfizer-believes-in-the-metaverse-will-healthcare-thaw-the-technologys-winter Sat, 18 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/heor-explained-improving-healthcare-decisions-with-real-world-evidence https://spypharm.com/heor-explained-improving-healthcare-decisions-with-real-world-evidence Sat, 18 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/mega-ma-at-jp-morgan-conference-2025-is-biopharma-ma-poised-for-a-rebound https://spypharm.com/mega-ma-at-jp-morgan-conference-2025-is-biopharma-ma-poised-for-a-rebound Sat, 18 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/charles-river-and-akron-link-to-integrate-cytokines-into-cell-therapy https://spypharm.com/charles-river-and-akron-link-to-integrate-cytokines-into-cell-therapy Sat, 18 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/copd-market-to-expand-with-astrazenecas-focus-on-biologics-and-strong-portfolio-growth https://spypharm.com/copd-market-to-expand-with-astrazenecas-focus-on-biologics-and-strong-portfolio-growth Sat, 18 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/impact-ovarian-cancer-capsules-authorised-in-china https://spypharm.com/impact-ovarian-cancer-capsules-authorised-in-china Sat, 18 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/jpm-2025-lonza-shares-outlook-on-chi-exit-and-acquisition-strategy https://spypharm.com/jpm-2025-lonza-shares-outlook-on-chi-exit-and-acquisition-strategy Sat, 18 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/shionogi-awarded-375m-from-hhs-for-preventative-covid-19-injectable https://spypharm.com/shionogi-awarded-375m-from-hhs-for-preventative-covid-19-injectable Sat, 18 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/abbvie-and-simcere-zaiming-link-to-develop-trispecific-antibody https://spypharm.com/abbvie-and-simcere-zaiming-link-to-develop-trispecific-antibody Thu, 16 Jan 2025 06:00:22 -0500 spectro https://spypharm.com/jp-morgan-2025-incyte-expects-period-of-defining-catalysts https://spypharm.com/jp-morgan-2025-incyte-expects-period-of-defining-catalysts Thu, 16 Jan 2025 06:00:22 -0500 spectro https://spypharm.com/bringing-engineering-to-a-new-level-zetas-integrated-approach https://spypharm.com/bringing-engineering-to-a-new-level-zetas-integrated-approach Thu, 16 Jan 2025 06:00:22 -0500 spectro https://spypharm.com/jp-morgan-2025-astrazeneca-promises-a-catalyst-rich-year-ahead https://spypharm.com/jp-morgan-2025-astrazeneca-promises-a-catalyst-rich-year-ahead Thu, 16 Jan 2025 06:00:19 -0500 spectro https://spypharm.com/regenxbio-and-nippon-shinyaku-forge-810m-gene-therapy-deal https://spypharm.com/regenxbio-and-nippon-shinyaku-forge-810m-gene-therapy-deal Thu, 16 Jan 2025 06:00:19 -0500 spectro https://spypharm.com/insmeds-gene-therapy-poised-to-challenge-dmd-landscape-after-ind-clearance https://spypharm.com/insmeds-gene-therapy-poised-to-challenge-dmd-landscape-after-ind-clearance Thu, 16 Jan 2025 06:00:19 -0500 spectro https://spypharm.com/lilly-gains-us-fda-approval-for-omvoh-to-treat-crohns-disease https://spypharm.com/lilly-gains-us-fda-approval-for-omvoh-to-treat-crohns-disease Thu, 16 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/be-bio-secures-92m-for-haemophilia-b-and-hypophosphatasia-treatments https://spypharm.com/be-bio-secures-92m-for-haemophilia-b-and-hypophosphatasia-treatments Thu, 16 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/jp-morgan-2025-abbvie-counts-on-skyrizi-and-rinvoq-to-fill-humira-sized-hole https://spypharm.com/jp-morgan-2025-abbvie-counts-on-skyrizi-and-rinvoq-to-fill-humira-sized-hole Thu, 16 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/charles-river-ceo-reveals-drop-in-2025-revenue-outlook-at-jp-morgan https://spypharm.com/charles-river-ceo-reveals-drop-in-2025-revenue-outlook-at-jp-morgan Thu, 16 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/biogen-proposes-acquisition-of-partner-sage-therapeutics https://spypharm.com/biogen-proposes-acquisition-of-partner-sage-therapeutics Tue, 14 Jan 2025 06:00:17 -0500 spectro https://spypharm.com/gilead-and-leo-pharma-link-on-programmes-for-inflammatory-conditions https://spypharm.com/gilead-and-leo-pharma-link-on-programmes-for-inflammatory-conditions Tue, 14 Jan 2025 06:00:17 -0500 spectro https://spypharm.com/pfizer-pitches-pipeline-priorities-in-oncology-and-obesity-at-jp-morgan-2025 https://spypharm.com/pfizer-pitches-pipeline-priorities-in-oncology-and-obesity-at-jp-morgan-2025 Tue, 14 Jan 2025 06:00:17 -0500 spectro https://spypharm.com/jp-morgan-2025-nvidia-partners-with-iqvia-illumina-and-mayo-clinic https://spypharm.com/jp-morgan-2025-nvidia-partners-with-iqvia-illumina-and-mayo-clinic Tue, 14 Jan 2025 06:00:17 -0500 spectro https://spypharm.com/small-matter-big-challenges-nano-milling-in-a-sterilised-environment https://spypharm.com/small-matter-big-challenges-nano-milling-in-a-sterilised-environment Tue, 14 Jan 2025 06:00:17 -0500 spectro https://spypharm.com/enhancing-patient-engagement-and-outcomes-in-the-nhs https://spypharm.com/enhancing-patient-engagement-and-outcomes-in-the-nhs Tue, 14 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-syngene https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-syngene Tue, 14 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-iff-pharma-solutions https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-iff-pharma-solutions Tue, 14 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-image-analysis-group https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-image-analysis-group Tue, 14 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/eli-lilly-targets-scorpion-therapeutics-to-expand-reach-in-oncology https://spypharm.com/eli-lilly-targets-scorpion-therapeutics-to-expand-reach-in-oncology Tue, 14 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/fda-cder-director-patrizia-cavazzoni-announces-resignation https://spypharm.com/fda-cder-director-patrizia-cavazzoni-announces-resignation Sun, 12 Jan 2025 06:00:12 -0500 spectro https://spypharm.com/climb-bio-enters-licensing-deal-with-mabworks-for-clym116-development https://spypharm.com/climb-bio-enters-licensing-deal-with-mabworks-for-clym116-development Sun, 12 Jan 2025 06:00:12 -0500 spectro https://spypharm.com/coave-therapeutics-raises-33m-in-funding-to-advance-aligater-platform https://spypharm.com/coave-therapeutics-raises-33m-in-funding-to-advance-aligater-platform Sun, 12 Jan 2025 06:00:12 -0500 spectro https://spypharm.com/alzheimers-total-prevalent-cases-to-reach-2251-million-in-8mm-in-2033 https://spypharm.com/alzheimers-total-prevalent-cases-to-reach-2251-million-in-8mm-in-2033 Sun, 12 Jan 2025 06:00:12 -0500 spectro https://spypharm.com/a2-biotherapeutics-raises-80m-to-advance-car-t-therapies-for-solid-tumours https://spypharm.com/a2-biotherapeutics-raises-80m-to-advance-car-t-therapies-for-solid-tumours Sun, 12 Jan 2025 06:00:12 -0500 spectro https://spypharm.com/light-horse-emerges-with-62m-and-novartis-partnership-worth-up-to-1bn https://spypharm.com/light-horse-emerges-with-62m-and-novartis-partnership-worth-up-to-1bn Sun, 12 Jan 2025 06:00:12 -0500 spectro https://spypharm.com/novo-nordisk-and-valo-expand-cardiometabolic-drug-partnership https://spypharm.com/novo-nordisk-and-valo-expand-cardiometabolic-drug-partnership Fri, 10 Jan 2025 06:00:19 -0500 spectro https://spypharm.com/sanofi-taps-alloy-therapeutics-for-cns-antisense-drug-development https://spypharm.com/sanofi-taps-alloy-therapeutics-for-cns-antisense-drug-development Fri, 10 Jan 2025 06:00:19 -0500 spectro https://spypharm.com/clinical-trial-trends-in-2025-investment-headwinds-wearables-and-targeted-ai-uses https://spypharm.com/clinical-trial-trends-in-2025-investment-headwinds-wearables-and-targeted-ai-uses Fri, 10 Jan 2025 06:00:19 -0500 spectro https://spypharm.com/msds-hpv-vaccine-gains-china-nmpas-expanded-approval-for-males https://spypharm.com/msds-hpv-vaccine-gains-china-nmpas-expanded-approval-for-males Fri, 10 Jan 2025 06:00:19 -0500 spectro https://spypharm.com/newron-and-myung-in-pharm-sign-agreement-for-evenamide-development https://spypharm.com/newron-and-myung-in-pharm-sign-agreement-for-evenamide-development Fri, 10 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/samsung-biologics-and-ligachem-extend-adc-services-deal https://spypharm.com/samsung-biologics-and-ligachem-extend-adc-services-deal Fri, 10 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/aspect-biosystems-secures-115m-to-develop-tissue-therapeutics https://spypharm.com/aspect-biosystems-secures-115m-to-develop-tissue-therapeutics Fri, 10 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/synaffix-secures-adc-deals-with-boehringer-and-mitsubishi-tanabe https://spypharm.com/synaffix-secures-adc-deals-with-boehringer-and-mitsubishi-tanabe Fri, 10 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/uk-based-verdiva-launches-with-410m-and-an-oral-glp-1ra-candidate https://spypharm.com/uk-based-verdiva-launches-with-410m-and-an-oral-glp-1ra-candidate Fri, 10 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/palforzias-peanut-allergy-treatment-use-in-europe-expanded-to-toddlers https://spypharm.com/palforzias-peanut-allergy-treatment-use-in-europe-expanded-to-toddlers Fri, 10 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/covid-19-the-global-clinical-trial-landscape-in-2024 https://spypharm.com/covid-19-the-global-clinical-trial-landscape-in-2024 Wed, 08 Jan 2025 06:00:19 -0500 spectro https://spypharm.com/danish-biotech-orbis-secures-94m-to-develop-oral-versions-of-biologics https://spypharm.com/danish-biotech-orbis-secures-94m-to-develop-oral-versions-of-biologics Wed, 08 Jan 2025 06:00:19 -0500 spectro https://spypharm.com/fda-awards-gsa-breakthrough-status-for-relapsed-osteosarcoma-treatment https://spypharm.com/fda-awards-gsa-breakthrough-status-for-relapsed-osteosarcoma-treatment Wed, 08 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/candid-therapeutics-signs-925m-t-cell-engager-deal-with-wuxi-biologics https://spypharm.com/candid-therapeutics-signs-925m-t-cell-engager-deal-with-wuxi-biologics Wed, 08 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/fda-accepts-sentynls-menkes-disease-therapy-nda-for-priority-review https://spypharm.com/fda-accepts-sentynls-menkes-disease-therapy-nda-for-priority-review Wed, 08 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/fda-grants-odd-to-tempests-hepatocellular-carcinoma-treatment https://spypharm.com/fda-grants-odd-to-tempests-hepatocellular-carcinoma-treatment Wed, 08 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/calls-for-increased-education-and-support-for-sickle-cell-blood-therapy-in-us https://spypharm.com/calls-for-increased-education-and-support-for-sickle-cell-blood-therapy-in-us Wed, 08 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/acelyrin-stock-plunges-after-positive-phase-ii-data-readout-in-thyroid-eye-disease https://spypharm.com/acelyrin-stock-plunges-after-positive-phase-ii-data-readout-in-thyroid-eye-disease Wed, 08 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/variant-bio-and-novo-nordisk-to-identify-targets-for-metabolic-disease-treatment https://spypharm.com/variant-bio-and-novo-nordisk-to-identify-targets-for-metabolic-disease-treatment Wed, 08 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/wuxi-biologics-to-sell-ireland-based-vaccine-site-to-msd-for-500m https://spypharm.com/wuxi-biologics-to-sell-ireland-based-vaccine-site-to-msd-for-500m Wed, 08 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/gcc-4001-by-artiva-biotherapeutics-for-rheumatoid-arthritis-likelihood-of-approval https://spypharm.com/gcc-4001-by-artiva-biotherapeutics-for-rheumatoid-arthritis-likelihood-of-approval Mon, 06 Jan 2025 06:00:21 -0500 spectro https://spypharm.com/hlc-001-by-human-life-cord-japan-for-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval https://spypharm.com/hlc-001-by-human-life-cord-japan-for-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval Mon, 06 Jan 2025 06:00:20 -0500 spectro https://spypharm.com/cd19-cd22-car-t-cells-by-shanghai-biomed-union-biotechnology-for-unspecified-b-cell-lymphomas-likelihood-of-approval https://spypharm.com/cd19-cd22-car-t-cells-by-shanghai-biomed-union-biotechnology-for-unspecified-b-cell-lymphomas-likelihood-of-approval Mon, 06 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/nmda-regulator-by-boehringer-ingelheim-international-for-unspecified-central-nervous-system-disorders-likelihood-of-approval https://spypharm.com/nmda-regulator-by-boehringer-ingelheim-international-for-unspecified-central-nervous-system-disorders-likelihood-of-approval Mon, 06 Jan 2025 06:00:17 -0500 spectro https://spypharm.com/paclitaxel-by-innoup-farma-for-solid-tumor-likelihood-of-approval https://spypharm.com/paclitaxel-by-innoup-farma-for-solid-tumor-likelihood-of-approval Mon, 06 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/fosigotifator-by-calico-life-sciences-for-unspecified-central-nervous-system-disorders-likelihood-of-approval https://spypharm.com/fosigotifator-by-calico-life-sciences-for-unspecified-central-nervous-system-disorders-likelihood-of-approval Mon, 06 Jan 2025 06:00:14 -0500 spectro https://spypharm.com/coronavirus-disease-2019-covid-19-vaccine-by-china-national-biotec-group-for-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval https://spypharm.com/coronavirus-disease-2019-covid-19-vaccine-by-china-national-biotec-group-for-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval Mon, 06 Jan 2025 06:00:13 -0500 spectro https://spypharm.com/abu-dhabi-stem-cells-center-develops-clinical-grade-ipscs https://spypharm.com/abu-dhabi-stem-cells-center-develops-clinical-grade-ipscs Mon, 06 Jan 2025 06:00:11 -0500 spectro https://spypharm.com/chinas-nmpa-approves-gsks-nucala-for-crswnp-treatment https://spypharm.com/chinas-nmpa-approves-gsks-nucala-for-crswnp-treatment Mon, 06 Jan 2025 06:00:11 -0500 spectro https://spypharm.com/bnt-325-by-biontech-for-malignant-mesothelioma-likelihood-of-approval https://spypharm.com/bnt-325-by-biontech-for-malignant-mesothelioma-likelihood-of-approval Mon, 06 Jan 2025 06:00:11 -0500 spectro https://spypharm.com/neumora-shares-sink-following-phase-iii-flop-in-mdd https://spypharm.com/neumora-shares-sink-following-phase-iii-flop-in-mdd Sat, 04 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/uk-mhra-approves-msds-pulmonary-arterial-hypertension-therapy https://spypharm.com/uk-mhra-approves-msds-pulmonary-arterial-hypertension-therapy Sat, 04 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/the-unmet-need-in-t2-low-asthma-a-critical-gap-in-treatment https://spypharm.com/the-unmet-need-in-t2-low-asthma-a-critical-gap-in-treatment Sat, 04 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/leading-strategic-intelligence-solutions-for-the-pharmaceteutical-industry https://spypharm.com/leading-strategic-intelligence-solutions-for-the-pharmaceteutical-industry Sat, 04 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/tirzepatide-outpacing-wegovy-in-the-obesity-space https://spypharm.com/tirzepatide-outpacing-wegovy-in-the-obesity-space Sat, 04 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/expanding-diagnostic-and-biomarker-options-to-improve-mash-clinical-trials https://spypharm.com/expanding-diagnostic-and-biomarker-options-to-improve-mash-clinical-trials Sat, 04 Jan 2025 06:00:14 -0500 spectro https://spypharm.com/from-davids-to-goliaths-the-glp-1ra-gold-rush https://spypharm.com/from-davids-to-goliaths-the-glp-1ra-gold-rush Sat, 04 Jan 2025 06:00:14 -0500 spectro https://spypharm.com/sigas-antiviral-approved-in-japan-for-orthopoxvirus-treatment https://spypharm.com/sigas-antiviral-approved-in-japan-for-orthopoxvirus-treatment Sat, 04 Jan 2025 06:00:14 -0500 spectro https://spypharm.com/iit-guwahati-and-bose-institute-develop-injectable-hydrogel-for-cancer https://spypharm.com/iit-guwahati-and-bose-institute-develop-injectable-hydrogel-for-cancer Sat, 04 Jan 2025 06:00:14 -0500 spectro https://spypharm.com/chinas-nmpa-prioritises-hutchmeds-lung-cancer-therapy-review https://spypharm.com/chinas-nmpa-prioritises-hutchmeds-lung-cancer-therapy-review Sat, 04 Jan 2025 06:00:14 -0500 spectro https://spypharm.com/innovent-and-roche-link-on-lung-cancer-therapy-development https://spypharm.com/innovent-and-roche-link-on-lung-cancer-therapy-development Thu, 02 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/sangamos-stock-sinks-50-as-pfizer-halts-haemophilia-a-gene-therapy-partnership https://spypharm.com/sangamos-stock-sinks-50-as-pfizer-halts-haemophilia-a-gene-therapy-partnership Thu, 02 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/tevimbra-by-beigene-for-muscle-invasive-bladder-cancer-mibc-likelihood-of-approval https://spypharm.com/tevimbra-by-beigene-for-muscle-invasive-bladder-cancer-mibc-likelihood-of-approval Tue, 31 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/tevimbra-by-beigene-for-gallbladder-cancer-likelihood-of-approval https://spypharm.com/tevimbra-by-beigene-for-gallbladder-cancer-likelihood-of-approval Tue, 31 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/ct-7439-by-carrick-therapeutics-for-breast-cancer-likelihood-of-approval https://spypharm.com/ct-7439-by-carrick-therapeutics-for-breast-cancer-likelihood-of-approval Tue, 31 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/iptacopan-hydrochloride-by-novartis-for-granulomatosis-with-polyangiitis-wegeners-granulomatosis-likelihood-of-approval https://spypharm.com/iptacopan-hydrochloride-by-novartis-for-granulomatosis-with-polyangiitis-wegeners-granulomatosis-likelihood-of-approval Tue, 31 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/itm-91-by-itm-isotope-technologies-munich-for-metastatic-colorectal-cancer-likelihood-of-approval https://spypharm.com/itm-91-by-itm-isotope-technologies-munich-for-metastatic-colorectal-cancer-likelihood-of-approval Tue, 31 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/itm-91-by-itm-isotope-technologies-munich-for-pancreatic-ductal-adenocarcinoma-likelihood-of-approval https://spypharm.com/itm-91-by-itm-isotope-technologies-munich-for-pancreatic-ductal-adenocarcinoma-likelihood-of-approval Tue, 31 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/tebapivat-by-agios-pharmaceuticals-for-sickle-cell-disease-likelihood-of-approval https://spypharm.com/tebapivat-by-agios-pharmaceuticals-for-sickle-cell-disease-likelihood-of-approval Tue, 31 Dec 2024 06:00:14 -0500 spectro https://spypharm.com/lxe-408-by-novartis-for-chagas-disease-american-trypanosomiasis-likelihood-of-approval https://spypharm.com/lxe-408-by-novartis-for-chagas-disease-american-trypanosomiasis-likelihood-of-approval Tue, 31 Dec 2024 06:00:14 -0500 spectro https://spypharm.com/xaluritamig-by-amgen-for-prostate-cancer-likelihood-of-approval https://spypharm.com/xaluritamig-by-amgen-for-prostate-cancer-likelihood-of-approval Tue, 31 Dec 2024 06:00:14 -0500 spectro https://spypharm.com/nvp-1805r2-by-nvp-healthcare-for-unspecified-cardiovascular-disorders-likelihood-of-approval https://spypharm.com/nvp-1805r2-by-nvp-healthcare-for-unspecified-cardiovascular-disorders-likelihood-of-approval Tue, 31 Dec 2024 06:00:14 -0500 spectro https://spypharm.com/tricaprilin-by-cerecin-for-infantile-spasm-west-syndrome-likelihood-of-approval https://spypharm.com/tricaprilin-by-cerecin-for-infantile-spasm-west-syndrome-likelihood-of-approval Fri, 27 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/nelivaptan-by-hmnc-for-major-depressive-disorder-likelihood-of-approval https://spypharm.com/nelivaptan-by-hmnc-for-major-depressive-disorder-likelihood-of-approval Fri, 27 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/darigabat-by-cerevel-therapeutics-for-seizures-likelihood-of-approval https://spypharm.com/darigabat-by-cerevel-therapeutics-for-seizures-likelihood-of-approval Fri, 27 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/gene-therapy-to-target-gd2-for-oncology-by-bristol-myers-squibb-for-osteosarcoma-likelihood-of-approval https://spypharm.com/gene-therapy-to-target-gd2-for-oncology-by-bristol-myers-squibb-for-osteosarcoma-likelihood-of-approval Fri, 27 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/gene-therapy-to-target-gd2-for-oncology-by-bristol-myers-squibb-for-sarcomas-likelihood-of-approval https://spypharm.com/gene-therapy-to-target-gd2-for-oncology-by-bristol-myers-squibb-for-sarcomas-likelihood-of-approval Fri, 27 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/stemvacs-v-by-res-nova-bio-for-metastatic-breast-cancer-likelihood-of-approval https://spypharm.com/stemvacs-v-by-res-nova-bio-for-metastatic-breast-cancer-likelihood-of-approval Fri, 27 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/lidocaine-by-medrx-for-postherpetic-neuralgia-likelihood-of-approval https://spypharm.com/lidocaine-by-medrx-for-postherpetic-neuralgia-likelihood-of-approval Fri, 27 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/kgyy-15-by-op-t-mune-for-type-1-diabetes-juvenile-diabetes-likelihood-of-approval https://spypharm.com/kgyy-15-by-op-t-mune-for-type-1-diabetes-juvenile-diabetes-likelihood-of-approval Fri, 27 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/mankind-pharma-and-innovent-partner-for-sintilimab-commercialisation-in-india https://spypharm.com/mankind-pharma-and-innovent-partner-for-sintilimab-commercialisation-in-india Fri, 27 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/eisbach-bio-positions-hrd-targeting-therapy-to-supplant-parp-inhibitors https://spypharm.com/eisbach-bio-positions-hrd-targeting-therapy-to-supplant-parp-inhibitors Fri, 27 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/investors-optimistic-about-continued-biotech-and-medtech-ipo-resurgence-in-2025 https://spypharm.com/investors-optimistic-about-continued-biotech-and-medtech-ipo-resurgence-in-2025 Wed, 25 Dec 2024 06:00:16 -0500 spectro https://spypharm.com/vertex-secures-two-fda-wins-for-cystic-fibrosis-both-with-boxed-warnings https://spypharm.com/vertex-secures-two-fda-wins-for-cystic-fibrosis-both-with-boxed-warnings Wed, 25 Dec 2024 06:00:16 -0500 spectro https://spypharm.com/eli-lillys-uk-life-sciences-investment-a-pivotal-moment-says-analyst https://spypharm.com/eli-lillys-uk-life-sciences-investment-a-pivotal-moment-says-analyst Wed, 25 Dec 2024 06:00:16 -0500 spectro https://spypharm.com/gemmabio-raises-34m-to-advance-gene-therapy-programmes https://spypharm.com/gemmabio-raises-34m-to-advance-gene-therapy-programmes Wed, 25 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/astrazenecas-tagrisso-gains-ec-approval-for-nsclc-treatment https://spypharm.com/astrazenecas-tagrisso-gains-ec-approval-for-nsclc-treatment Wed, 25 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/sk-bioscience-and-sanofi-expand-agreement-for-pneumococcal-conjugate-vaccines https://spypharm.com/sk-bioscience-and-sanofi-expand-agreement-for-pneumococcal-conjugate-vaccines Wed, 25 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/novo-gets-the-green-light-for-once-daily-haemophilia-drug-following-setbacks https://spypharm.com/novo-gets-the-green-light-for-once-daily-haemophilia-drug-following-setbacks Wed, 25 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/rapt-therapeutics-and-shanghai-jemincare-sign-anti-ige-antibody-agreement https://spypharm.com/rapt-therapeutics-and-shanghai-jemincare-sign-anti-ige-antibody-agreement Wed, 25 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/fda-approves-lillys-obesity-med-zepbound-to-treat-obstructive-sleep-apnoea https://spypharm.com/fda-approves-lillys-obesity-med-zepbound-to-treat-obstructive-sleep-apnoea Wed, 25 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/pfizers-colorectal-cancer-combo-therapy-gains-accelerated-approval-from-fda https://spypharm.com/pfizers-colorectal-cancer-combo-therapy-gains-accelerated-approval-from-fda Mon, 23 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/astellas-and-sangamo-sign-capsid-deal-for-neurological-diseases https://spypharm.com/astellas-and-sangamo-sign-capsid-deal-for-neurological-diseases Sat, 21 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/vertexs-stock-hurt-after-non-opioid-pain-drug-shows-benefit-similar-to-placebo https://spypharm.com/vertexs-stock-hurt-after-non-opioid-pain-drug-shows-benefit-similar-to-placebo Sat, 21 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/fda-approves-mesoblasts-ryoncil-for-sr-agvhd-treatment https://spypharm.com/fda-approves-mesoblasts-ryoncil-for-sr-agvhd-treatment Sat, 21 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/msd-makes-obesity-play-in-up-to-2bn-deal-for-hansohs-glp-1ra-asset https://spypharm.com/msd-makes-obesity-play-in-up-to-2bn-deal-for-hansohs-glp-1ra-asset Sat, 21 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/palleon-and-shanghai-henlius-biotech-link-on-autoimmune-therapy https://spypharm.com/palleon-and-shanghai-henlius-biotech-link-on-autoimmune-therapy Sat, 21 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/magazine-us-reproductive-laws-could-limit-womens-participation-in-clinical-trials https://spypharm.com/magazine-us-reproductive-laws-could-limit-womens-participation-in-clinical-trials Sat, 21 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/fda-approves-ionis-tryngolza-for-fcs-treatment https://spypharm.com/fda-approves-ionis-tryngolza-for-fcs-treatment Sat, 21 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/novo-nordisk-takes-a-hit-as-cagrisema-underperforms-in-weight-loss https://spypharm.com/novo-nordisk-takes-a-hit-as-cagrisema-underperforms-in-weight-loss Sat, 21 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/fda-confirms-end-of-eli-lillys-tirzepatide-shortage-after-re-evaluation https://spypharm.com/fda-confirms-end-of-eli-lillys-tirzepatide-shortage-after-re-evaluation Sat, 21 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/setback-for-uk-pharma-as-government-sets-unexpectedly-high-vpag-payback-rate-in-2025 https://spypharm.com/setback-for-uk-pharma-as-government-sets-unexpectedly-high-vpag-payback-rate-in-2025 Sat, 21 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/oncology-rd-emerging-therapies-and-new-challenges https://spypharm.com/oncology-rd-emerging-therapies-and-new-challenges Thu, 19 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/fda-targets-more-online-vendors-selling-unapproved-glp-1ra-products https://spypharm.com/fda-targets-more-online-vendors-selling-unapproved-glp-1ra-products Thu, 19 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/gilead-and-terray-link-to-develop-small-molecule-therapies https://spypharm.com/gilead-and-terray-link-to-develop-small-molecule-therapies Thu, 19 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/egyptian-drug-authority-approves-lilly-and-evas-insulin-injection https://spypharm.com/egyptian-drug-authority-approves-lilly-and-evas-insulin-injection Thu, 19 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/novo-nordisk-invests-12bn-in-new-denmark-facility https://spypharm.com/novo-nordisk-invests-12bn-in-new-denmark-facility Thu, 19 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/novo-holdings-completes-catalent-acquisition-for-165bn https://spypharm.com/novo-holdings-completes-catalent-acquisition-for-165bn Thu, 19 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/pharmas-data-and-analytics-market-forecast-to-reach-to-21bn-by-2028 https://spypharm.com/pharmas-data-and-analytics-market-forecast-to-reach-to-21bn-by-2028 Thu, 19 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/abera-and-orexo-partner-for-vaccine-powder-formulations https://spypharm.com/abera-and-orexo-partner-for-vaccine-powder-formulations Thu, 19 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/the-healthcare-sector-must-change-its-industrial-refrigeration-methods-to-reduce-its-emissions https://spypharm.com/the-healthcare-sector-must-change-its-industrial-refrigeration-methods-to-reduce-its-emissions Thu, 19 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/petrovax-announces-positive-results-from-long-cov-iii-21-trial-of-longidaza-for-long-term-pulmonary-sequelae-of-covid-19 https://spypharm.com/petrovax-announces-positive-results-from-long-cov-iii-21-trial-of-longidaza-for-long-term-pulmonary-sequelae-of-covid-19 Thu, 19 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/small-cell-lung-cancer-navigating-the-global-clinical-trial-landscape https://spypharm.com/small-cell-lung-cancer-navigating-the-global-clinical-trial-landscape Tue, 17 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/denmarks-hta-evolution https://spypharm.com/denmarks-hta-evolution Tue, 17 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/ema-recommends-expanding-approval-of-ofev-to-children-and-adolescents https://spypharm.com/ema-recommends-expanding-approval-of-ofev-to-children-and-adolescents Tue, 17 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/bavarian-nordic-signs-mpox-vax-deal-with-serum-institute-of-india https://spypharm.com/bavarian-nordic-signs-mpox-vax-deal-with-serum-institute-of-india Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/cto-europe-2024-keep-the-burden-of-trials-away-from-patients-say-experts https://spypharm.com/cto-europe-2024-keep-the-burden-of-trials-away-from-patients-say-experts Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/gsks-lung-cancer-therapy-gains-ema-prime-designation https://spypharm.com/gsks-lung-cancer-therapy-gains-ema-prime-designation Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/adcs-breach-barriers-to-become-mainstream-cancer-treatment https://spypharm.com/adcs-breach-barriers-to-become-mainstream-cancer-treatment Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/fda-approves-galdermas-nemluvio-to-treat-atopic-dermatitis https://spypharm.com/fda-approves-galdermas-nemluvio-to-treat-atopic-dermatitis Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/the-future-of-third-party-logistics-in-an-evolving-biopharmaceutical-world https://spypharm.com/the-future-of-third-party-logistics-in-an-evolving-biopharmaceutical-world Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/reprieve-for-wuxi-as-biosecure-vote-likely-pushed-to-2025 https://spypharm.com/reprieve-for-wuxi-as-biosecure-vote-likely-pushed-to-2025 Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-cullinan-therapeuticss-cln-619 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-cullinan-therapeuticss-cln-619 Sun, 15 Dec 2024 06:00:13 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-avidity-biosciencess-aoc-1020 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-avidity-biosciencess-aoc-1020 Sun, 15 Dec 2024 06:00:13 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-in8bios-inb-400 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-in8bios-inb-400 Sun, 15 Dec 2024 06:00:12 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-vigil-neurosciences-iluzanebart https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-vigil-neurosciences-iluzanebart Sun, 15 Dec 2024 06:00:12 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-aquestive-therapeuticss-epinephrine https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-aquestive-therapeuticss-epinephrine Sun, 15 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-jazz-pharmaceuticalss-jzp-898 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-jazz-pharmaceuticalss-jzp-898 Sun, 15 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-solid-biosciencess-sgt-003 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-solid-biosciencess-sgt-003 Sun, 15 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-forte-biosciencess-fb-102 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-forte-biosciencess-fb-102 Sun, 15 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-tenaya-therapeuticss-tn-401 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-tenaya-therapeuticss-tn-401 Sun, 15 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-crispr-therapeuticss-ctx-131 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-crispr-therapeuticss-ctx-131 Sun, 15 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-i-mabs-lemzoparlimab https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-i-mabs-lemzoparlimab Fri, 13 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-pfizers-clesacostat-tromethamine-ervogastat https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-pfizers-clesacostat-tromethamine-ervogastat Fri, 13 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-adicet-bios-adi-001 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-adicet-bios-adi-001 Fri, 13 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-eli-lilly-and-cos-imlunestrant-tosylate https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-eli-lilly-and-cos-imlunestrant-tosylate Fri, 13 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-novartiss-rapcabtagene-autoleucel https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-novartiss-rapcabtagene-autoleucel Fri, 13 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/flu-vaccine-strategy-on-the-line-as-new-us-leaders-anticipated-to-take-charge https://spypharm.com/flu-vaccine-strategy-on-the-line-as-new-us-leaders-anticipated-to-take-charge Fri, 13 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-rallybios-rlyb-116 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-rallybios-rlyb-116 Fri, 13 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/aim-immunotech-gains-netherlands-patent-for-post-covid-fatigue-therapy https://spypharm.com/aim-immunotech-gains-netherlands-patent-for-post-covid-fatigue-therapy Fri, 13 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-oric-pharmaceuticalss-oric-944 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-oric-pharmaceuticalss-oric-944 Fri, 13 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-plus-therapeuticss-rhenium-186re-obisbemeda https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-plus-therapeuticss-rhenium-186re-obisbemeda Fri, 13 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/seres-ser-155-gains-breakthrough-status-for-bsis-reduction https://spypharm.com/seres-ser-155-gains-breakthrough-status-for-bsis-reduction Wed, 11 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/fda-to-review-gsks-nucala-for-copd https://spypharm.com/fda-to-review-gsks-nucala-for-copd Wed, 11 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/new-amsterdam-stock-jumps-as-ldl-c-lowering-drug-scores-again-at-phase-iii https://spypharm.com/new-amsterdam-stock-jumps-as-ldl-c-lowering-drug-scores-again-at-phase-iii Wed, 11 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/ema-validates-chiesi-and-protalixs-dose-variation-for-fabry-disease https://spypharm.com/ema-validates-chiesi-and-protalixs-dose-variation-for-fabry-disease Wed, 11 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/rsv-prophylactic-market-to-reach-62bn-in-8mm-by-2030 https://spypharm.com/rsv-prophylactic-market-to-reach-62bn-in-8mm-by-2030 Wed, 11 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/santheras-dmd-therapy-agamree-approved-for-nhs-use-after-new-price-deal https://spypharm.com/santheras-dmd-therapy-agamree-approved-for-nhs-use-after-new-price-deal Wed, 11 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/lillys-279m-bet-aims-to-boost-uk-life-sciences-sector https://spypharm.com/lillys-279m-bet-aims-to-boost-uk-life-sciences-sector Wed, 11 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/dr-myles-greenberg-becomes-president-and-ceo-of-incarda-therapeutics https://spypharm.com/dr-myles-greenberg-becomes-president-and-ceo-of-incarda-therapeutics Wed, 11 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/ash-2024-jjs-tecvayli-shows-promise-in-transplant-eligible-ndmm-patient https://spypharm.com/ash-2024-jjs-tecvayli-shows-promise-in-transplant-eligible-ndmm-patient Wed, 11 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/ash-2024-regenerons-ordspono-faces-challenges-but-positive-results-signal-hope https://spypharm.com/ash-2024-regenerons-ordspono-faces-challenges-but-positive-results-signal-hope Wed, 11 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/priority-fda-review-given-to-astrazenecas-imfinzi-sbla-for-mibc https://spypharm.com/priority-fda-review-given-to-astrazenecas-imfinzi-sbla-for-mibc Mon, 09 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/fda-rmat-status-for-affimed-and-artivas-lymphoma-combo-therapy https://spypharm.com/fda-rmat-status-for-affimed-and-artivas-lymphoma-combo-therapy Mon, 09 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/dewpoint-therapeutics-and-mitsubishi-tanabe-link-on-als-treatment https://spypharm.com/dewpoint-therapeutics-and-mitsubishi-tanabe-link-on-als-treatment Sat, 07 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/leo-pharmas-eczema-cream-gains-mhra-marketing-authorisation https://spypharm.com/leo-pharmas-eczema-cream-gains-mhra-marketing-authorisation Sat, 07 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/merus-bizengri-granted-fda-accelerated-approval-to-treat-nrg1-cancers https://spypharm.com/merus-bizengri-granted-fda-accelerated-approval-to-treat-nrg1-cancers Sat, 07 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/fda-shares-new-draft-guidance-for-accelerated-approval https://spypharm.com/fda-shares-new-draft-guidance-for-accelerated-approval Sat, 07 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/new-study-finds-obesity-costs-us-industry-347bn-a-year https://spypharm.com/new-study-finds-obesity-costs-us-industry-347bn-a-year Sat, 07 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/eli-lilly-to-invest-3bn-in-wisconsin-facility-expansion https://spypharm.com/eli-lilly-to-invest-3bn-in-wisconsin-facility-expansion Sat, 07 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/centenarians-unlocking-the-secrets-of-living-to-100 https://spypharm.com/centenarians-unlocking-the-secrets-of-living-to-100 Sat, 07 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/muna-gsk-alliance-to-fast-track-alzheimers-disease-treatments https://spypharm.com/muna-gsk-alliance-to-fast-track-alzheimers-disease-treatments Sat, 07 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/fda-armat-status-for-affimed-and-artivas-lymphoma-combo-therapy https://spypharm.com/fda-armat-status-for-affimed-and-artivas-lymphoma-combo-therapy Sat, 07 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/cell-and-gene-therapy-companies-must-demonstrate-strong-value-proposition-for-investment https://spypharm.com/cell-and-gene-therapy-companies-must-demonstrate-strong-value-proposition-for-investment Sat, 07 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/lundbeck-acquires-all-outstanding-shares-of-longboard-pharma https://spypharm.com/lundbeck-acquires-all-outstanding-shares-of-longboard-pharma Thu, 05 Dec 2024 06:00:19 -0500 spectro https://spypharm.com/fda-approves-astrazenecas-imfinzi-to-treat-ls-sclc https://spypharm.com/fda-approves-astrazenecas-imfinzi-to-treat-ls-sclc Thu, 05 Dec 2024 06:00:18 -0500 spectro https://spypharm.com/ceo-of-unitedhealthcare-brian-thompson-shot-dead-in-new-york-city https://spypharm.com/ceo-of-unitedhealthcare-brian-thompson-shot-dead-in-new-york-city Thu, 05 Dec 2024 06:00:18 -0500 spectro https://spypharm.com/lillys-zepbound-wins-the-weight-loss-duel-with-novos-wegovy https://spypharm.com/lillys-zepbound-wins-the-weight-loss-duel-with-novos-wegovy Thu, 05 Dec 2024 06:00:18 -0500 spectro https://spypharm.com/ipsen-and-biomunex-enter-agreement-for-cancer-therapy https://spypharm.com/ipsen-and-biomunex-enter-agreement-for-cancer-therapy Thu, 05 Dec 2024 06:00:18 -0500 spectro https://spypharm.com/takeda-licensed-for-anaemia-therapy-by-keros-therapeutics https://spypharm.com/takeda-licensed-for-anaemia-therapy-by-keros-therapeutics Thu, 05 Dec 2024 06:00:18 -0500 spectro https://spypharm.com/trump-20-could-see-a-rise-in-biopharmaceutical-ma-deals https://spypharm.com/trump-20-could-see-a-rise-in-biopharmaceutical-ma-deals Thu, 05 Dec 2024 06:00:18 -0500 spectro https://spypharm.com/from-cobenfy-to-emraclidine-the-muscarinic-path-to-safer-antipsychotics https://spypharm.com/from-cobenfy-to-emraclidine-the-muscarinic-path-to-safer-antipsychotics Thu, 05 Dec 2024 06:00:18 -0500 spectro https://spypharm.com/maze-therapeutics-raises-115m-to-advance-kidney-disease-candidates https://spypharm.com/maze-therapeutics-raises-115m-to-advance-kidney-disease-candidates Thu, 05 Dec 2024 06:00:18 -0500 spectro https://spypharm.com/all-in-one-milling-platforms-how-to-reduce-your-machinery-footprint https://spypharm.com/all-in-one-milling-platforms-how-to-reduce-your-machinery-footprint Thu, 05 Dec 2024 06:00:18 -0500 spectro https://spypharm.com/cbc-acquires-ucbs-neurology-and-allergy-business-in-china https://spypharm.com/cbc-acquires-ucbs-neurology-and-allergy-business-in-china Tue, 03 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/uq-secures-funds-for-development-of-skin-cancer-prevention-cream https://spypharm.com/uq-secures-funds-for-development-of-skin-cancer-prevention-cream Tue, 03 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/prep-therapies-offer-new-hope-in-hiv-preventive-landscape-as-vaccine-failures-amass https://spypharm.com/prep-therapies-offer-new-hope-in-hiv-preventive-landscape-as-vaccine-failures-amass Tue, 03 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/novartis-and-ptc-therapeutics-link-to-develop-huntingtons-therapy https://spypharm.com/novartis-and-ptc-therapeutics-link-to-develop-huntingtons-therapy Tue, 03 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/fate-therapeutics-makes-bob-valamehr-president-and-ceo https://spypharm.com/fate-therapeutics-makes-bob-valamehr-president-and-ceo Tue, 03 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/jjs-sblas-seek-fda-approval-of-tremfya-for-paediatric-conditions https://spypharm.com/jjs-sblas-seek-fda-approval-of-tremfya-for-paediatric-conditions Tue, 03 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/faron-pharma-secures-uk-innovation-passport-for-blood-cancer-immunotherapy https://spypharm.com/faron-pharma-secures-uk-innovation-passport-for-blood-cancer-immunotherapy Tue, 03 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/chmp-recommends-oral-peanut-allergy-immunotherapy-treatment-for-toddlers https://spypharm.com/chmp-recommends-oral-peanut-allergy-immunotherapy-treatment-for-toddlers Tue, 03 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/ema-launches-esmp-for-better-management-of-drug-shortages-in-eu https://spypharm.com/ema-launches-esmp-for-better-management-of-drug-shortages-in-eu Sun, 01 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/university-of-birmingham-identifies-target-to-reduce-gvhd-risk https://spypharm.com/university-of-birmingham-identifies-target-to-reduce-gvhd-risk Sun, 01 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/uk-government-to-launch-first-ever-mens-health-strategy https://spypharm.com/uk-government-to-launch-first-ever-mens-health-strategy Sun, 01 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/prep-therapies-utter-new-hope-in-hiv-preventive-landscape-as-vaccine-failures-amass https://spypharm.com/prep-therapies-utter-new-hope-in-hiv-preventive-landscape-as-vaccine-failures-amass Sun, 01 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/uk-reports-near-eradication-of-meningitis-c-amid-declining-vaccine-uptake https://spypharm.com/uk-reports-near-eradication-of-meningitis-c-amid-declining-vaccine-uptake Sun, 01 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/kronos-bio-announces-interim-ceo-and-workforce-cuts-of-83 https://spypharm.com/kronos-bio-announces-interim-ceo-and-workforce-cuts-of-83 Fri, 29 Nov 2024 06:00:10 -0500 spectro https://spypharm.com/trump-agency-nominations-show-pharma-industry-as-divided-as-us https://spypharm.com/trump-agency-nominations-show-pharma-industry-as-divided-as-us Fri, 29 Nov 2024 06:00:10 -0500 spectro https://spypharm.com/health-canada-approves-novo-nordisks-wegovy-to-cut-heart-attacks https://spypharm.com/health-canada-approves-novo-nordisks-wegovy-to-cut-heart-attacks Fri, 29 Nov 2024 06:00:10 -0500 spectro https://spypharm.com/combatting-infectious-disease-challenges-and-opportunities-for-pharma-in-the-green-transition https://spypharm.com/combatting-infectious-disease-challenges-and-opportunities-for-pharma-in-the-green-transition Fri, 29 Nov 2024 06:00:10 -0500 spectro https://spypharm.com/cervomeds-stock-rises-as-fda-grants-orphan-drug-status-to-dementia-drug https://spypharm.com/cervomeds-stock-rises-as-fda-grants-orphan-drug-status-to-dementia-drug Fri, 29 Nov 2024 06:00:10 -0500 spectro https://spypharm.com/wait-for-galactosemia-therapy-goes-on-after-fda-shuns-applied-therapeutics-govorestat https://spypharm.com/wait-for-galactosemia-therapy-goes-on-after-fda-shuns-applied-therapeutics-govorestat Fri, 29 Nov 2024 06:00:10 -0500 spectro https://spypharm.com/allink-biotherapeutics-secures-funding-to-advance-adc-pipeline https://spypharm.com/allink-biotherapeutics-secures-funding-to-advance-adc-pipeline Fri, 29 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/formosa-and-medvisis-agree-on-post-operative-eye-pain-therapy https://spypharm.com/formosa-and-medvisis-agree-on-post-operative-eye-pain-therapy Fri, 29 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/trump-20-spells-global-change-in-pharmaceutical-regulation-funding-and-investment https://spypharm.com/trump-20-spells-global-change-in-pharmaceutical-regulation-funding-and-investment Fri, 29 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/advanz-pharmas-liver-disease-drug-pulled-from-european-market-after-court-hearing https://spypharm.com/advanz-pharmas-liver-disease-drug-pulled-from-european-market-after-court-hearing Fri, 29 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/eton-acquires-us-rights-to-neonatal-diabetes-treatment-from-ammtek https://spypharm.com/eton-acquires-us-rights-to-neonatal-diabetes-treatment-from-ammtek Wed, 27 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/roche-to-acquire-poseida-therapeutics-for-15bn https://spypharm.com/roche-to-acquire-poseida-therapeutics-for-15bn Wed, 27 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/shorla-oncologys-imkeldi-approved-by-fda-for-leukaemia-cancers https://spypharm.com/shorla-oncologys-imkeldi-approved-by-fda-for-leukaemia-cancers Wed, 27 Nov 2024 06:00:11 -0500 spectro